GLP-1R / GIPR / GCGR triple agonist analogs and their uses

By developing polypeptides or derivatives thereof with GLP-1R/GIPR/GCGR triple receptor agonistic activity, the problems of short half-life, low bioavailability and obvious side effects of existing GLP-1 analogs in the treatment of diabetes and obesity are solved. , achieving more effective blood sugar control and weight loss, with higher safety and a wide range of benefits.

CN117586374BActive Publication Date: 2024-11-29SHENZHEN BAY LAB
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311295490.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-07
Publication Date
2024-11-29
Estimated Expiration
2043-10-07

AI Technical Summary

Technical Problem

The existing GLP-1 analogs have problems such as short half-life, low bioavailability, obvious side effects and low compliance in the treatment of diabetes and obesity, making it difficult to effectively control blood sugar and weight loss.

Method used

Develop a polypeptide or derivative thereof with GLP-1R/GIPR/GCGR triple receptor agonistic activity and structure of formula (I), which supports low frequency and high efficiency drug administration by improving the stability and duration of action of the drug. .

Benefits of technology

This polypeptide or its derivatives can effectively control blood sugar and weight loss, and is used to prevent or treat metabolic disorder-related diseases, bone-related diseases, cardiovascular diseases and neurodegenerative diseases, and has a high safety and benefit range.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure QLYQS_2
    Figure QLYQS_2
  • Figure QLYQS_3
    Figure QLYQS_3
Patent Text Reader

Abstract

The present invention discloses a polypeptide or its derivative or a pharmaceutically acceptable salt thereof. The polypeptide or its derivative has a structure shown in formula (I): X1X2X3GTX6X7X8DX 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 X 24 X 25 LX 27 X 28 X 29 X 30 PX 32 SX 34 X 35 PPPX 39 (I); The structure shown in formula (I) contains two amino acids with ‑SH in the side chain or two amino acids with ‑NH2 in the side chain, and ‑SH or ‑NH2 is used to connect the modifying group. The above-mentioned polypeptide or its derivative or their pharmaceutically acceptable salts show strong agonist activity on the three receptor targets of GLP-1R, GCGR and GIPR, can effectively control blood sugar and reduce body weight, and can be used to prevent or treat diseases related to metabolic disorders.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biopharmaceutical technology. Specifically, the present invention relates to a GLP-1R / GIPR / GCGR triple agonist analog and its use. More specifically, the present invention relates to a polypeptide or its derivative or their pharmaceutically acceptable salts, a pharmaceutical composition and their use. Background Art

[0002] Diabetes (e.g., type 2 diabetes, T2DM) is a type of energy metabolism disorder that has become an increasingly serious health problem in many countries and has caused a wide range of related dangerous diseases, such as cardiovascular and cerebrovascular diseases, dyslipidemia, kidney disease, liver disease, osteoporosis, and neurodegenerative diseases. The main feature of type 2 diabetes is hyperglycemia caused by insulin resistance, and obesity is one of the main causes of insulin resistance. Obesity is a state in which excessive fat accumulates in the body due to excessive energy intake or metabolic abnormalities. This excessive fat accumulation may damage the function of pancreatic islet cells and aggravate the condition of diabetes. In addition, obesity and insulin resistance are also two major pathogenic factors of non-alcoholic fatty liver disease (NAFLD / NASH). Therefore, there is an urgent need to find safe and effective drugs to treat these metabolic disorder-related diseases. At the same time, for the increasing number of obese people, there is an urgent need for a therapeutic drug with better effects, wider benefits, and higher safety to control weight.

[0003] Incretin is a substance secreted by the intestine under normal physiological conditions, including glucose-dependent insulin polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG). Its secretion is regulated by glucose levels, and it has the functions of maintaining the function of pancreatic β cells, stimulating pancreatic β cells to secrete insulin, regulating the stability of glucose levels, inhibiting gastric acid secretion, delaying gastric emptying, increasing satiety, and regulating fat metabolism. These functions are of great significance for the treatment and management of diabetes, obesity and related metabolic diseases.

[0004] Glucagon-like peptide-1 (GLP-1) is a polypeptide expressed by the proglucagon gene in the intestinal mucosal L cells and consists of 31 amino acids. GLP-1 mainly stimulates insulin secretion, inhibits glucagon secretion, protects pancreatic β cells, and regulates blood sugar homeostasis by binding to the GLP-1 receptor (GLP-1R). In addition, GLP-1 can also inhibit appetite and gastric emptying through the central nervous system signaling pathway, increase satiety, and thus reduce body weight.

[0005] Glucagon-dependent insulin-releasing polypeptide (GIP) is a 42-amino acid single-chain polypeptide produced by K cells in the small intestinal mucosa. GIP mainly acts on GIP receptors (GIPR) in pancreatic islet cells and adipocytes. GIP can regulate glucose metabolism by promoting insulin secretion, enhancing the mass of pancreatic β cells, inhibiting gastric acid secretion and slowing down gastric motility. In addition, GIP can also stimulate the uptake and utilization of fatty acids by adipose tissue cells. Studies have also shown that GIP also has a physiological effect of protecting bones in terms of promoting osteoblast differentiation, inhibiting osteoblast apoptosis, inhibiting bone resorption and increasing bone mineral density.

[0006] Glucagon (GCG) is a 29-amino acid polypeptide secreted by pancreatic alpha cells. It mainly acts on the glucagon receptor (GCGR) mainly distributed in the liver and kidneys. GCG can stimulate liver glycogenolysis, increase blood sugar levels, activate lipase, promote fat decomposition, and enhance fatty acid oxidation, thereby increasing the production of ketone bodies. Research results show that GCG has a certain effect on reducing food intake, increasing energy consumption of adipose tissue, and reducing body fat content.

[0007] Therefore, there is an urgent need to develop an incretin analog that is active on the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinogenic polypeptide receptor (GIPR) and glucagon receptor (GCGR) at the same time, so as to effectively treat metabolic disorders such as diabetes. Summary of the invention

[0008] The present invention aims to solve at least one of the technical problems existing in the prior art to a certain extent. To this end, the present invention provides a GLP-1R / GIPR / GCGR triple agonist analog, which has the agonist activity of glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinogenic polypeptide receptor (GIPR) and glucagon receptor (GCGR) at the same time.

[0009] The present invention is accomplished based on the following findings of the inventors:

[0010] Natural GLP-1 is easily degraded by dipeptidyl peptidase-IV (DPP-IV) and neutral endopeptidase (NEP) which are commonly found in plasma, and has a half-life of less than 2 minutes. In order to improve the half-life of GLP-1 and the effect of diabetes treatment, there are currently a variety of GLP-1 analogs that can be used to treat T2DM, including Exenatide, Liraglutide and Semaglutide. Currently, GLP-1 drugs used for obesity generally reduce weight by about 5-10%, and the overall average weight loss ratio does not exceed 10% of the patient's body weight. At the same time, many GLP-1 analogs on the market currently have limited dosage due to gastrointestinal side effects such as nausea and vomiting.

[0011] In addition, some GLP-1R / GCGR dual agonists developed based on gastrin (Oxyntomodulin) are also believed to have better effects in reducing food intake, lowering body weight, and improving blood sugar and triglyceride levels than GLP-1R single agonists. However, the development of peptide drugs on the market is often hindered by short half-life and low bioavailability. Patients tend to receive higher doses of therapeutic drugs more frequently, which may lead to reduced compliance, increased costs and increased risk of side effects. Therefore, the present invention has developed a therapeutic agent with balanced GLP-1R / GIPR / GCGR triple receptor agonist activity, good stability, and a sufficiently long duration of action to support low-frequency, high-efficiency dosing, for example, once a week, once every two weeks, or even once a month.

[0012] Based on this, in the first aspect of the present invention, the present invention provides a polypeptide or a derivative thereof or a pharmaceutically acceptable salt thereof. According to an embodiment of the present invention, the polypeptide or a derivative thereof has a structure shown in formula (I):

[0013] X 1 X 2 X 3 GTX 6 X 7 X 8 DX 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 X 24 X 25 LX 27 X 28X 29 X 30

[0014] PX 32 SX 34 X 35 PPPX 39 (I);

[0015] Among them, X 1 is Y, H, 3-iodo-Y, 4-Pal or 4-amino-F;

[0016] X 2 is Aib, s or Ac4c;

[0017] X 3 is Q, H or Dab(Ac);

[0018] X 6 is F, F(2-F) or αMeF;

[0019] X 8 is S, HoS or αMeS;

[0020] X 10 Z 2 , Y, Z 1 , L or 4-Pal;

[0021] X 11 is S or αMeS;

[0022] X 12 is K, R or I;

[0023] X 13 Z 2 , Z 1 , Y, L, A, αMeL, Q, Aib or Iva;

[0024] X 14 Z 2 , Z 1 , L, K(Ac), HoL, Npg or Tle;

[0025] X 15 is D, E or Aad;

[0026] X 16 is K, E, K(Ac) or αMeK;

[0027] X 17 R, Z 2 , Z 1 , K(Ac), Q or I;

[0028] X 18 Z2 , Z 1 , A, R or Y;

[0029] X 19 is A, Q, Aib, H or K(Ac);

[0030] X 20 Q, Z 2 , Aib, H, R, a, or Z 1 ;

[0031] X 21 Z 1 , D, A, L, Z 2 or Aib;

[0032] X 22 is F or HoF;

[0033] X 23 V or I;

[0034] X 24 Z 2 , Q, Z 1 or E;

[0035] X 25 Z 2 , Z 1 , W or Y;

[0036] X 27 is L, K or I;

[0037] X 28 for A, D, E, Z 1 or Z 2 ;

[0038] X 29 is G or H;

[0039] X 30 is G or H;

[0040] X 32 Z 2 , Z 1 , S or P;

[0041] X 34 is G or Aib;

[0042] X 35 A, Q or K;

[0043] X 39 is S or K;

[0044] In the structure represented by formula (I), the two positions in any of the following groups are independently selected from amino acids Z having -SH in the side chain: 1, or the two sites in any of the following groups in the structure represented by formula (I) are independently selected from the side chain containing -NH 2 The amino acid Z 2 :

[0045] 1)i and i+3;

[0046] 2)i and i+4;

[0047] 3) i and i+7; or

[0048] 4)i and i+11;

[0049] Wherein, i is 10, 14, 17 or 21;

[0050] Two amino acids Z containing -SH in the side chain 1 Each is independently selected from C, C, αMeC, HoC, Hoc, Pen or N-Me-C;

[0051] Both of the side chains contain -NH 2 The amino acid Z 2 Each is independently selected from K, k, αMeK, HoK, Dap, Dab, Orn or N-Me-K.

[0052] The above-mentioned polypeptide or its derivatives or their pharmaceutically acceptable salts of the present invention can be used as incretin analogs, which can show strong agonist activity on the three receptor targets of GLP-1R, GCGR and GIPR, can effectively control blood sugar and reduce body weight, and can be used to prevent or treat metabolic disorder-related diseases, bone-related diseases, cardiovascular diseases and neurodegenerative diseases, etc.

[0053] In the second aspect of the present invention, the present invention provides a polypeptide derivative or a pharmaceutically acceptable salt thereof, characterized in that the polypeptide derivative has any structure shown in Table A (see the claims for details).

[0054] In the third aspect of the present invention, the present invention proposes a pharmaceutical composition. According to an embodiment of the present invention, the pharmaceutical composition comprises the polypeptide or its derivatives or their pharmaceutically acceptable salts described in the first aspect, or the polypeptide derivatives or their pharmaceutically acceptable salts described in the second aspect. As mentioned above, the polypeptide or its derivatives or their pharmaceutically acceptable salts of the present invention exhibit strong agonist activity on the three receptor targets of GLP-1R, GCGR and GIPR, and can effectively control blood sugar and reduce body weight. Therefore, the use of drugs containing polypeptides or their derivatives or their pharmaceutically acceptable salts can effectively prevent or treat metabolic disorder-related diseases, bone-related diseases, cardiovascular diseases and neurodegenerative diseases, etc.

[0055] In the fourth aspect of the present invention, the present invention proposes a use of the polypeptide or its derivative or their pharmaceutically acceptable salts described in the first aspect, the polypeptide derivative or their pharmaceutically acceptable salts described in the second aspect, or the pharmaceutical composition described in the third aspect in the preparation of a drug, wherein the drug is used to treat or prevent at least one of metabolic disorder-related diseases, bone-related diseases, cardiovascular diseases and neurodegenerative diseases.

[0056] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 This is the synthetic route of Staple-A1 in Example 1 of the present invention.

[0058] Figure 2 It is a schematic diagram of the steps of connecting the linear peptide TG30 and Staple-A1 in Example 1 of the present invention.

[0059] Figure 3 Schematic diagram of the steps of connecting linear peptide TG85 and Stable B1 in Example 2 of the present invention.

[0060] Figure 4 This is the body weight change curve of C57BL / 6J mice after they were injected with different doses of the compound TG52 of the present invention in Test Example 3 of the present invention.

[0061] Figure 5 This is the curve of the change of daily total food intake of each group of mice after different doses of the compound TG52 of the present invention were injected into C57BL / 6J mice in Test Example 3 of the present invention.

[0062] Figure 6 This is the curve of changes in blood glucose levels of C57BL / 6J mice after they were injected with different doses of the compound TG52 of the present invention in Test Example 3 of the present invention. DETAILED DESCRIPTION

[0063] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.

[0064] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.

[0065] Detailed description of the invention

[0066] Definitions and general terms

[0067] In this document, the terms “include” or “comprising” are open expressions, that is, including the contents specified in the present invention but not excluding other contents.

[0068] As used herein, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0069] In this document, the terms "optionally substituted", "optionally substituted" and "substituted or unsubstituted" are used interchangeably. In general, the term "optionally", whether or not it is preceded by the term "substituted", means that one or more hydrogen atoms in a given structure are replaced by a specific substituent. Unless otherwise indicated, an optional substituent group can be substituted at each substitutable position of the group. When more than one position in a given structural formula can be substituted by one or more substituents selected from a specific group, the substituents can be substituted at each position in the same or different manner. The substituents described can be, but are not limited to, F, Cl, Br, CN, OH, NH 2 、NO 2 wait.

[0070] As used herein, the term "one or more" (e.g. in the definition of substituents of the compounds of the general formula of the invention (modifying groups)) means "one, two, three, four or five, especially one, two, three or four, more especially one, two or three, even more especially one or two".

[0071] In addition, it should be noted that, unless explicitly stated otherwise, the description methods used in the present invention, "each... is independently" and "... are each independently" and "... are independently" can be interchanged and should be understood in a broad sense, which can mean that in different groups, the specific options expressed by the same symbols do not affect each other, or that in the same group, the specific options expressed by the same symbols do not affect each other.

[0072] As used herein, the term "halogen" refers to a fluorine, chlorine, bromine or iodine atom.

[0073] In this document, the minimum and maximum carbon atom content in a hydrocarbon group is indicated by a prefix, for example, the prefix C a~b It means containing "a" to "b" carbon atoms. 1~n” refers to a straight or branched saturated / unsaturated carbon chain containing 1, 2, 3, 4, 5, ... or n carbon atoms; further understand that “C 1~n " shall be interpreted as including any sub-ranges included therein, such as C 1~20 Including C 1~20 , C 1~18 , C 10~8 , C 12~18 , C 14~18 , C 1~10 , C 1~6 , C 1~3 , C 1~2 , C 2~10 , C 2~9 , C 2~8 , C 2~7 , C 2~6 , C 2~5 , C 2~4 , C 2~3 , C 3~10 , C 3~9 , C 3~8 , C 3~7 , C 3~6 , C 3~5 , C 3~4 , C 4~10 , C 4~9 , C 4~8 , C 4~7 , C 4~6 , C 4~5 .

[0074] In this context, the term "alkyl" has the general structure of The alkylene group may be a straight chain alkyl group or a branched chain alkyl group. 1~20 "Alkyl" refers to an alkyl group having 1 to 20 carbon atoms; the term "C 1~6 The term "alkyl" refers to an alkyl group having 1 to 6 carbon atoms.

[0075] As used herein, the term "alkylene" is The alkylene group may be a straight chain alkylene group or a branched chain alkylene group. 1~20 "Alkylene" refers to an alkylene group having 1 to 20 carbon atoms; the term "C 1~6 The term "alkylene" refers to an alkylene group having 1 to 6 carbon atoms.

[0076] In this article, the term “C 1~6 "Alkoxy" refers to a C 1~6Alkyl, wherein the term "alkyl" is as defined above. For example: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, sec-butoxy, pentyloxy, isopentyloxy and n-hexyloxy, or isomers of the above groups. In particular, the "C 1~6 The "alkoxy" group may contain 1, 2, 3, 4 or 5 carbon atoms ("C 1~5 Alkoxy”), preferably, may contain 1, 2, 3 or 4 carbon atoms (“C 1~4 "alkoxy").

[0077] As used herein, the term "oxyalkylene" refers to a group formed by removing a hydrogen atom from an "oxyalkyl" group.

[0078] In this article, the term "aryl" refers to a carbocyclic ring system containing monocyclic, bicyclic and tricyclic rings, wherein at least one ring system is aromatic, wherein each ring system contains a ring composed of 3-10 atoms. The aryl group is usually, but not necessarily, connected to the parent molecule through the aromatic ring of the aryl group. The term "aryl" can be used interchangeably with the term "aromatic ring" or "aromatic ring". The aryl group can include phenyl, indenyl, naphthyl and anthracenyl. The aryl group is optionally substituted by one or more substituents described in the present disclosure.

[0079] As used herein, the term "arylene" refers to a group formed by removing a hydrogen atom from an "aryl" group.

[0080] As used herein, the term "heteroaryl" refers to a carbon ring system containing monocyclic, bicyclic and tricyclic rings containing at least one heteroatom, wherein at least one ring system is aromatic. Here, heteroatoms refer to nitrogen atoms, oxygen atoms, sulfur atoms, etc. It generally refers to a monovalent saturated or partially unsaturated monocyclic or bicyclic ring system of multiple ring atoms, which contains 1, 2 or 3 ring heteroatoms selected from N, O and S, and the remaining ring atoms are carbon.

[0081] As used herein, the term "heteroarylene" refers to a group formed by removing a hydrogen atom from a "heteroaryl" group.

[0082] The group description of the present invention It is used to describe the position of group substitution.

[0083] As used herein, the structural formula of the term "-NH-CO-" or "-NH-C(=O)-" is

[0084] The amino acids herein are referred to by the conventional one-letter and three-letter codes for naturally occurring amino acids, as well as the commonly accepted three-letter codes for other α-amino acids, for example, α-aminoisobutyric acid can be represented by both codes Aib or B. Unless otherwise specified, all amino acid residues in the present invention are preferably in the L-configuration.

[0085] Among them, the structural formula of the term "Aib" is

[0086] In this context, the structural formula of the term "Ac4c" is

[0087] As used herein, the structural formula of the term "αMeC" is

[0088] In this context, the structural formula of the term "αMeL" is

[0089] In this context, the structural formula of the term "αMeS" is

[0090] As used herein, the structural formula of the term "αMeF" is

[0091] In this context, the structural formula of the term "αMeK" is As used herein, the structural formula of the term "Iva" is As used herein, the structural formula of the term "F(2-F)" is As used herein, the structural formula of the term "4-Pal" is In this context, the structural formula of the term "K(Ac)" is In this context, the term "HoL" has the structural formula In this document, the structural formula of the term "Tle" is As used herein, the structural formula of the term "Npg" is In this context, the term "HoC" has the structural formula In this context, the structural formula of the term "Hoc" is In this context, the term "HoF" has the structural formula In this context, the term "HoS" has the structural formula In this context, the term "HoK" has the structural formula In this context, the structural formula of the term "3-iodo-Y" is As used herein, the structural formula of the term "4-amino-F" is As used herein, the structural formula of the term "Dab(Ac)" is

[0092] In this document, the structural formula of the term "Aad" is

[0093] In this document, the structural formula of the term "Pen" is

[0094] As used herein, the structural formula of the term "N-Me-C" is

[0095] In this context, the structural formula of the term "N-Me-K" is

[0096] In this document, the structural formula of the term "Orn" is

[0097] In this context, the structural formula of the term "Dab" is

[0098] As used herein, the structural formula of the term "Dap" is

[0099] In this article, "pharmaceutical composition" may refer to a composition used for the treatment of a disease, and may also be used for in vitro cell culture experiments. When used for the treatment of a disease, the term "pharmaceutical composition" generally refers to a unit dosage form, and may be prepared by any of the methods well known in the pharmaceutical field. All methods include the step of combining the active ingredient with an excipient that constitutes one or more accessory ingredients. Typically, the composition is prepared by uniformly and fully combining the active polypeptide or its derivative or revitalizing agent with a liquid excipient, a finely divided solid excipient, or both.

[0100] In this article, the term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with other ingredients comprising the polypeptide or its derivatives and / or the mammals treated therewith. Preferably, the "pharmaceutically acceptable" of the present invention refers to those approved by federal regulatory agencies or national governments or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopeias for use in animals, particularly humans.

[0101] In this article, the term "pharmaceutically acceptable salt" refers to organic salts and inorganic salts of the polypeptide of the present invention or its derivatives. Pharmaceutically acceptable salts are well known in the art, as described in the literature: SM Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1-19. Pharmaceutically acceptable salts formed by non-toxic acids include, but are not limited to, inorganic acid salts (such as hydrochlorides, hydrobromides, phosphates, sulfates, perchlorates) formed by reaction with amino groups, and organic acid salts (such as acetates, oxalates, maleates, tartrates, citrates, succinates, malonates), or other methods described in books and literature, such as ion exchange methods, to obtain these salts.

[0102] In the chemical structure of the ligand or compound disclosed in the present invention, the bond Indicates that the configuration is not specified. If chiral isomerism exists in the chemical structure, the bond Can be or include both Although all of the above structural formulae are drawn in certain isomeric forms for simplicity, the present disclosure may include all isomers, for example, tautomers, rotational isomers, geometric isomers, diastereomers, racemates, and enantiomers.

[0103] In this article, the term "pharmaceutically acceptable excipient" may include any solvent, solid excipient, diluent or other liquid excipient, etc., suitable for a specific target dosage form. Except for any conventional excipients incompatible with the polypeptide or derivative thereof, pharmaceutical composition or drug containing them of the present invention, such as any adverse biological effect produced or interaction with any other component of the pharmaceutically acceptable composition in a harmful manner, their use is also within the scope of the present invention.

[0104] In addition to any conventional excipients, to the extent that they are incompatible with the polypeptides or derivatives thereof, pharmaceutical compositions or drugs containing them of the present invention, such as any adverse biological effects produced or interactions with any other components of the pharmaceutically acceptable composition in a harmful manner, their use is also within the scope of the present invention.

[0105] The pharmaceutical compositions disclosed herein include preparations suitable for parenteral administration. The preparations can be conveniently present in unit dosage form and can be prepared by any method known in the pharmaceutical field. The amount of active ingredient that can be combined with auxiliary materials to prepare a single dose form is generally the amount of polypeptide or its derivative that produces a therapeutic effect.

[0106] As used herein, the term "agonist" refers to a substance (ligand) which activates the receptor type in question.

[0107] As used herein, the term "treatment" refers to the use of drugs to obtain the desired pharmacological and / or physiological effects. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in an individual who is susceptible to the disease but has not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the progression of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a polypeptide or a derivative thereof to an individual to treat, cure, alleviate, improve, mitigate or inhibit an individual's disease, including but not limited to administering a drug containing a polypeptide or a derivative thereof as described herein to an individual in need.

[0108] In this article, the term "non-alcoholic fatty liver disease (NAFLD)" generally refers to a clinical pathological syndrome characterized by excessive fat deposition in hepatocytes excluding alcohol and other clear liver-damaging factors, and is an acquired metabolic stress-induced liver injury closely related to insulin resistance and genetic susceptibility, including but not limited to simple fatty liver (SFL), non-alcoholic steatohepatitis (NASH) and its related cirrhosis.

[0109] Detailed description of the polypeptide or its derivatives or their pharmaceutically acceptable salts, pharmaceutical compositions and their uses of the present invention

[0110] The present invention provides a polypeptide or its derivatives or their pharmaceutically acceptable salts, a pharmaceutical composition and their uses, which will be described in detail below.

[0111] Polypeptide or its derivative or their pharmaceutically acceptable salt

[0112] In the first aspect of the present invention, the present invention provides a polypeptide or a derivative thereof or a pharmaceutically acceptable salt thereof. According to an embodiment of the present invention, the polypeptide or a derivative thereof has a structure shown in formula (I):

[0113] X 1 X 2 X 3 GTX 6 X 7 X 8 DX 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X21 X 22 X 23 X 24 X 25 LX 27 X 28 X 29 X 30

[0114] PX 32 SX 34 X 35 PPPX 39 (I);

[0115] Among them, X 1 is Y, H, 3-iodo-Y, 4-Pal or 4-amino-F;

[0116] X 2 is Aib, s or Ac4c;

[0117] X 3 is Q, H or Dab(Ac);

[0118] X 6 is F, F(2-F) or αMeF;

[0119] X 8 is S, HoS or αMeS;

[0120] X 10 Z 2 , Y, Z 1 , L or 4-Pal;

[0121] X 11 is S or αMeS;

[0122] X 12 is K, R or I;

[0123] X 13 Z 2 , Z 1 ,Y,L,A,αMeL,Q,Aib,Iva;

[0124] X 14 Z 2 , Z 1 , L, K(Ac), HoL, Npg or Tle;

[0125] X 15 is D, E or Aad;

[0126] X 16 is K, E, K(Ac) or αMeK;

[0127] X17 R, Z 2 , Z 1 , K(Ac), Q or I;

[0128] X 18 Z 2 , Z 1 , A, R or Y;

[0129] X 19 is A, Q, Aib, H or K(Ac);

[0130] X 20 Q, Z 2 , Aib, H, R, a, or Z 1 ;

[0131] X 21 Z 1 , D, A, L, Z 2 or Aib;

[0132] X 22 is F or HoF;

[0133] X 23 V or I;

[0134] X 24 Z 2 , Q, Z 1 or E;

[0135] X 25 Z 2 , Z 1 , W or Y;

[0136] X 27 is L, K or I;

[0137] X 28 for A, D, E, Z 1 or Z 2 ;

[0138] X 29 is G or H;

[0139] X 30 is G or H;

[0140] X 32 Z 2 , Z 1 , S or P;

[0141] X 34 is G or Aib;

[0142] X 35 A, Q or K;

[0143] X 39 is S or K;

[0144] In the structure represented by formula (I), the two positions in any of the following groups are independently selected from amino acids Z having -SH in the side chain: 1 , or the two sites in any of the following groups in the structure represented by formula (I) are independently selected from the side chain containing -NH 2 The amino acid Z 2 :

[0145] 1)i and i+3;

[0146] 2)i and i+4;

[0147] 3) i and i+7; or

[0148] 4)i and i+11;

[0149] Wherein, i is 10, 14, 17 or 21;

[0150] Two amino acids Z containing -SH in the side chain 1 Each is independently selected from C, C, αMeC, HoC, Hoc, Pen or N-Me-C;

[0151] Both of the side chains contain -NH 2 The amino acid Z 2 Each is independently selected from K, k, αMeK, HoK, Dap, Dab, Orn or N-Me-K.

[0152] The above-mentioned polypeptide or its derivatives or their pharmaceutically acceptable salts of the present invention show strong agonist activity on the three receptor targets of GLP-1R, GCGR and GIPR, can effectively control blood sugar and reduce body weight, and can be used to prevent or treat metabolic disorder-related diseases, bone-related diseases, cardiovascular diseases and neurodegenerative diseases, etc.

[0153] Unless otherwise specified, in this article, for amino acids with single-letter abbreviations, capital letters represent L-configuration amino acids (e.g., S (i.e., L-configuration Ser), A (i.e., L-configuration Ala), etc.), and lowercase letters represent D-configuration amino acids (e.g., s (i.e., D-configuration Ser), a (i.e., D-configuration Ala), etc.).

[0154] In this article, X in the structure shown in formula (I) i represents an amino acid, where i represents the position of the amino acid. 9 It is the ninth amino acid in the structure shown in formula (I).

[0155] It should be explained that the two positions in group 1) are i and i+3 respectively; the two positions in group 2) are i and i+4 respectively; the two positions in group 3) are i and i+7 respectively; the two positions in group 4) are i and i+11 respectively. In addition, the two positions in groups 1) to 4) are both amino acids Z 1 , or two positions in groups 1) to 4) are amino acid Z at the same time 2 Among them, the two amino acids Z in each group of sites 1 Can be the same or different, the two amino acids Z in each group of sites 2 Can be the same or different.

[0156] In some preferred embodiments of the present invention, the two amino acids Z in the structure shown in formula (I) 1 same.

[0157] In some preferred embodiments of the present invention, the two amino acids Z in the structure shown in formula (I) 2 same.

[0158] According to an embodiment of the present invention, the two amino acids Z in the structure shown in formula (I) contain -SH in the side chains 1 The positions of are i and i+3, i and i+4, i and i+7, or i and i+11, and i is 10, 14, 17 or 21.

[0159] According to an embodiment of the present invention, the two amino acids Z in the structure shown in formula (I) contain -SH in the side chains 1 The positions of are i and i+3 respectively, i is 10, 14, 17 or 21, and preferably i is 17.

[0160] According to an embodiment of the present invention, the two amino acids Z in the structure shown in formula (I) contain -SH in the side chains 1 The positions of are i and i+4 respectively, i is 10, 14, 17 or 21, and preferably i is 10.

[0161] According to an embodiment of the present invention, the two amino acids Z in the structure shown in formula (I) contain -SH in the side chains 1 The positions of are i and i+7 respectively, i is 10, 14, 17 or 21, preferably i is 14, 17 or 21.

[0162] According to an embodiment of the present invention, the two amino acids Z in the structure shown in formula (I) contain -SH in the side chains 1 The positions of are i and i+11 respectively, i is 10, 14, 17 or 21, preferably i is 10 or 17.

[0163] According to an embodiment of the present invention, the two side chains in the structure shown in formula (I) contain -NH2 The amino acid Z 2 The positions of are i and i+3, i and i+4, i and i+7, or i and i+11, and i is 10, 14, 17 or 21.

[0164] According to an embodiment of the present invention, the two side chains in the structure shown in formula (I) contain -NH 2 The amino acid Z 2 The positions are i+3, or i and i+7, and i is 17 or 21.

[0165] According to an embodiment of the present invention, the two side chains in the structure shown in formula (I) contain -NH 2 The amino acid Z 2 The positions are 17 and 20, or 21 and 28 respectively.

[0166] According to an embodiment of the present invention, X 1 It is Y or H.

[0167] According to an embodiment of the present invention, X 2 It is Aib or Ac4c.

[0168] According to an embodiment of the present invention, X 3 It is Q or H.

[0169] According to an embodiment of the present invention, X 6 is F or F(2-F).

[0170] According to an embodiment of the present invention, X 6 is F(2-F).

[0171] According to an embodiment of the present invention, X 10 It is Y, C, L or 4-Pal.

[0172] According to an embodiment of the present invention, X 10 It is Y, L or 4-Pal.

[0173] According to an embodiment of the present invention, X 10 It is Y or 4-Pal.

[0174] According to an embodiment of the present invention, X 11 is S or αMeS.

[0175] According to an embodiment of the present invention, X 12 It is K or I.

[0176] According to an embodiment of the present invention, X 13 It is Y, L, A, αMeL, Q, Aib or Iva.

[0177] According to an embodiment of the present invention, X13 is Y, L, αMeL, Q, Aib or Iva.

[0178] According to an embodiment of the present invention, X 13 It is Y, L, αMeL, Q or Iva.

[0179] According to an embodiment of the present invention, X 13 is L or αMeL.

[0180] According to an embodiment of the present invention, X 13 It is Y, L or A.

[0181] According to an embodiment of the present invention, X 13 It is αMeL, Y or Iva.

[0182] According to an embodiment of the present invention, X 13 It is αMeL, Q or L.

[0183] According to an embodiment of the present invention, X 13 It is Y or L.

[0184] According to an embodiment of the present invention, X 14 is L, K(Ac), HoL, Npg or Tle.

[0185] According to an embodiment of the present invention, X 14 is C, L, K(Ac), HoL, Npg or Tle.

[0186] According to an embodiment of the present invention, X 15 It is D or E.

[0187] According to an embodiment of the present invention, X 16 K or E.

[0188] According to an embodiment of the present invention, X 16 is E, K, αMeK or K(Ac).

[0189] According to an embodiment of the present invention, X 16 is K or αMeK.

[0190] According to an embodiment of the present invention, X 17 is C, Q, K(Ac), R or I.

[0191] According to an embodiment of the present invention, X 17 is R, K, K(Ac), Q or I.

[0192] According to an embodiment of the present invention, X 17 is K(Ac) or K.

[0193] According to an embodiment of the present invention, X17 is C or K(Ac).

[0194] According to an embodiment of the present invention, X 17 It is R, K or Q.

[0195] According to an embodiment of the present invention, X 18 A, R or Y.

[0196] According to an embodiment of the present invention, X 18 A or Y.

[0197] According to an embodiment of the present invention, X 19 It is A, Q or Aib.

[0198] According to an embodiment of the present invention, X 19 It is Q or A.

[0199] According to an embodiment of the present invention, X 19 It is Q or H.

[0200] According to an embodiment of the present invention, X 20 It is Q, K, Aib, H, a or C.

[0201] According to an embodiment of the present invention, X 20 It is Aib, Q, H, C or a.

[0202] According to an embodiment of the present invention, X 20 is Q, Aib, H or R.

[0203] According to an embodiment of the present invention, X 20 It is Q, K or Aib.

[0204] According to an embodiment of the present invention, X 20 Is Aib or Q.

[0205] According to an embodiment of the present invention, X 20 Is Aib or K.

[0206] According to an embodiment of the present invention, X 21 is C, D, A, L or Aib.

[0207] According to an embodiment of the present invention, X 21 It is D, A or C.

[0208] According to an embodiment of the present invention, X 21 D, A or L.

[0209] According to an embodiment of the present invention, X 21 It is K or A.

[0210] According to an embodiment of the present invention, X 21It is D or C.

[0211] According to an embodiment of the present invention, X 22 F or HoF.

[0212] According to an embodiment of the present invention, X 23 Is I or V.

[0213] According to an embodiment of the present invention, X 24 It is Q, C or E.

[0214] According to an embodiment of the present invention, X 24 It is E, C or Q.

[0215] According to an embodiment of the present invention, X 24 Is E or C.

[0216] According to an embodiment of the present invention, X 24 It is Q or E.

[0217] According to an embodiment of the present invention, X 25 W or Y.

[0218] According to an embodiment of the present invention, X 28 A, D, E, C or HoC.

[0219] According to an embodiment of the present invention, X 28 A, D or E.

[0220] According to an embodiment of the present invention, X 28 Either A or E.

[0221] According to an embodiment of the present invention, X 28 Is E or C.

[0222] According to an embodiment of the present invention, X 28 It is K or A.

[0223] According to an embodiment of the present invention, X 32 It is S or P.

[0224] According to an embodiment of the present invention, X 35 It is A or Q.

[0225] According to an embodiment of the present invention, X 35 It is A or K.

[0226] According to an embodiment of the present invention, X 39 is S, wherein the C-terminus of the S is amidated.

[0227] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivative has a structure represented by formula (Ia):

[0228] X 1 X 2 X 3 GTX 6 TSDX 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 FX 23 X 24 X 25 LLX 28 GGPSSGGPPPS

[0229] (Ia).

[0230] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 1 It is Y or H.

[0231] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 10 It is Y or 4-Pal.

[0232] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 12 It is K or I.

[0233] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 13 It is Y, L, αMeL, Q or Iva.

[0234] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 14 is C, L, K(Ac), HoL, Npg or Tle.

[0235] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 15 It is D or E.

[0236] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 16 is E, K, αMeK or K(Ac).

[0237] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 17 is C, Q, K(Ac), R or I.

[0238] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 18 A or Y.

[0239] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 19 It is Q or A.

[0240] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 20 It is Aib, Q, H, C or a.

[0241] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 21 It is D, A or C.

[0242] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 24 It is E, C or Q.

[0243] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 25 W or Y.

[0244] In some optional embodiments of the present invention, in the structure shown in formula (Ia), X 28 Is E or C.

[0245] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (Ia) have -SH side chains. 1 The positions are 14 and 21, 17 and 24, 21 and 28 or 17 and 20 respectively.

[0246] In some optional embodiments of the present invention, the two side chains in the structure shown in formula (Ia) contain -NH 2 The amino acid Z 2 The positions are 21 and 28 or 17 and 20 respectively.

[0247] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (Ia) have -SH side chains. 1 They are 14 and 21 respectively.

[0248] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (Ia) have -SH side chains. 1 They are 17 and 24 respectively.

[0249] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (Ia) have -SH side chains. 1 The positions are 21 and 28 respectively.

[0250] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (Ia) have -SH side chains. 1 The positions are 17 and 20 respectively.

[0251] In some optional embodiments of the present invention, in the structure shown in formula (Ia), the two amino acids Z 1 Each is independently selected from C, C, αMeC, HoC, Hoc, Pen or N-Me-C, preferably C, C, αMeC or HoC.

[0252] In some optional embodiments of the present invention, in the structure shown in formula (Ia), the two amino acids Z 1 Both are C.

[0253] In some optional embodiments of the present invention, in the structure shown in formula (Ia), the two amino acids Z 1 Both are c.

[0254] In some optional embodiments of the present invention, in the structure shown in formula (Ia), the two amino acids Z 1 All are αMeC.

[0255] In some optional embodiments of the present invention, in the structure shown in formula (Ia), the two amino acids Z 1 All are HoC.

[0256] In some optional embodiments of the present invention, the two side chains in the structure shown in formula (Ia) contain -NH 2 The amino acid Z 2 The positions are 21 and 28 respectively.

[0257] In some optional embodiments of the present invention, the two side chains in the structure shown in formula (Ia) contain -NH 2 The amino acid Z 2 The positions are 17 and 20 respectively.

[0258] In some optional embodiments of the present invention, in the structure shown in formula (Ia), the two amino acids Z 2 Each is independently selected from K, k, αMeK, HoK, Dap, Dab, Orn or N-Me-K, preferably K or Orn.

[0259] In some optional embodiments of the present invention, in the structure shown in formula (Ia), the two amino acids Z 2 Both are K.

[0260] In some optional embodiments of the present invention, in the structure shown in formula (Ia), the two amino acids Z 2 Both are Orn.

[0261] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivative has a structure represented by formula (Ib):

[0262] X 1 X 2 X 3 GTX 6 TSDY 11 X 12 X 13 LDX 16 X 17 X 18 X 19 X 20 X 21 FX 23 X 24 X 25 LLX 28 GGPSSGGPPPS

[0263] (Ib).

[0264] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 1 It is Y or H.

[0265] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 2 It is Aib or Ac4c.

[0266] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 3 It is Q or H.

[0267] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 6 is F or F(2-F).

[0268] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 11 is S or αMeS.

[0269] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 12 It is K or I.

[0270] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 13 It is αMeL, Y or Iva.

[0271] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 16 is K or αMeK.

[0272] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 17 is C or K(Ac).

[0273] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 18 A or Y.

[0274] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 19 It is Q or A.

[0275] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 20 Is Aib or Q.

[0276] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 21 It is D or C.

[0277] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 23 Is I or V.

[0278] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 24 Is E or C.

[0279] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 25 W or Y.

[0280] In some optional embodiments of the present invention, in the structure shown in formula (Ib), X 28 Is E or C.

[0281] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (Ib) have -SH side chains. 1 The positions are 17 and 24, or 21 and 28 respectively.

[0282] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (Ib) have -SH side chains. 1 The positions are 17 and 24 respectively.

[0283] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (Ib) have -SH side chains. 1 The positions are 21 and 28 respectively.

[0284] In some optional embodiments of the present invention, in the structure shown in formula (Ib), the two amino acids Z 1Each is independently selected from C, C, αMeC, HoC, Hoc, Pen or N-Me-C, preferably C, C, αMeC or HoC.

[0285] In some optional embodiments of the present invention, in the structure shown in formula (Ib), the two amino acids Z 1 Both are C.

[0286] In some optional embodiments of the present invention, in the structure shown in formula (Ib), the two amino acids Z 1 Both are c.

[0287] In some optional embodiments of the present invention, in the structure shown in formula (Ib), the two amino acids Z 1 All are αMeC.

[0288] In some optional embodiments of the present invention, in the structure shown in formula (Ib), the two amino acids Z 1 All are HoC.

[0289] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivative has a structure represented by formula (II):

[0290] The polypeptide represented by formula (I) or its derivative has a structure represented by formula (II):

[0291] X 1 X 2 X 3 GTX 6 X 7 X 8 DX 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 FX 23 X 24 X 25 LX 27 X 28 X 29 X 30 PX 32 SX

[0292] 34 X 35 PPPX 39

[0293] (II).

[0294] In some optional embodiments of the present invention, in the structure shown in formula (II), X 10 It is Y, C, L or 4-Pal.

[0295] In some optional embodiments of the present invention, in the structure shown in formula (II), X 13 It is Y, L, A, αMeL, Q, Aib or Iva.

[0296] In some optional embodiments of the present invention, in the structure shown in formula (II), X 14 is C, L, K(Ac), HoL, Npg or Tle.

[0297] In some optional embodiments of the present invention, in the structure shown in formula (II), X 18 A, R or Y.

[0298] In some optional embodiments of the present invention, in the structure shown in formula (II), X 21 is C, D, A, L or Aib.

[0299] In some optional embodiments of the present invention, in the structure shown in formula (II), X 24 It is Q, C or E.

[0300] In some optional embodiments of the present invention, in the structure shown in formula (II), X 25 W or Y.

[0301] In some optional embodiments of the present invention, in the structure shown in formula (II), X 28 A, D, E, C or HoC.

[0302] In some optional embodiments of the present invention, in the structure shown in formula (II), X 32 It is S or P.

[0303] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (II) have -SH side chains. 1 The positions are one of the following combinations:

[0304] i and i+3, i is 17;

[0305] i and i+4, i is 10;

[0306] i and i+7, i is 10, 14, 17 or 21; or

[0307] i and i+11, i is 10 or 17.

[0308] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (II) have -SH side chains. 1 The positions are 14 and 21 respectively.

[0309] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (II) have -SH side chains. 1 The positions are 17 and 20 respectively.

[0310] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (II) have -SH side chains. 1 The positions are 10 and 14 respectively.

[0311] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (II) have -SH side chains. 1 The positions are 10 and 17 respectively.

[0312] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (II) have -SH side chains. 1 The positions are 17 and 24 respectively.

[0313] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (II) have -SH side chains. 1 The positions are 21 and 28 respectively.

[0314] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (II) have -SH side chains. 1 The positions are 10 and 21 respectively.

[0315] In some optional embodiments of the present invention, the two amino acids Z in the structure shown in formula (II) have -SH side chains. 1 The positions are 17 and 28 respectively.

[0316] In some optional embodiments of the present invention, in the structure shown in formula (II), the two amino acids Z 1 Each is independently selected from C, C, αMeC, HoC, Hoc, Pen or N-Me-C, preferably C, C, αMeC or HoC.

[0317] In some optional embodiments of the present invention, in the structure shown in formula (II), the two amino acids Z 1 Both are C.

[0318] In some optional embodiments of the present invention, in the structure shown in formula (II), the two amino acids Z 1 Both are c.

[0319] In some optional embodiments of the present invention, in the structure shown in formula (II), the two amino acids Z 1 All are αMeC.

[0320] In some optional embodiments of the present invention, in the structure shown in formula (II), the two amino acids Z 1 All are HoC.

[0321] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivative has a structure represented by formula (III):

[0322] X 1 -Aib-X 3 GTX 6 TSDY 12 X 13 CCX 15 X 16 X 17 X 18 X 19 X 20 CCFX 23 X 24 X 25 LLX 28 X 29 X 30 PSSGX 3

[0323] 5 PPPS

[0324] (III).

[0325] In some optional embodiments of the present invention, in the structure shown in formula (III), X 1 It is Y or H.

[0326] In some optional embodiments of the present invention, in the structure shown in formula (III), X 3 It is Q or H, preferably H.

[0327] In some optional embodiments of the present invention, in the structure shown in formula (III), X 6 It is F or F(2-F), preferably F.

[0328] In some optional embodiments of the present invention, in the structure shown in formula (III), X 12 It is K or I, preferably I.

[0329] In some optional embodiments of the present invention, in the structure shown in formula (III), X 13 It is Y or L, preferably Y.

[0330] In some optional embodiments of the present invention, in the structure shown in formula (III), X 15 It is D or E, preferably E.

[0331] In some optional embodiments of the present invention, in the structure shown in formula (III), X 16 It is K or E, preferably K.

[0332] In some optional embodiments of the present invention, in the structure shown in formula (III), X 17 It is R, K or Q, preferably R.

[0333] In some optional embodiments of the present invention, in the structure shown in formula (III), X 18 A, R or Y, preferably Y.

[0334] In some optional embodiments of the present invention, in the structure shown in formula (III), X 19 A or Q, preferably A.

[0335] In some optional embodiments of the present invention, in the structure shown in formula (III), X 20 It is Q, K or Aib, preferably Aib.

[0336] In some optional embodiments of the present invention, in the structure shown in formula (III), X 24 It is Q or E, preferably Q.

[0337] In some optional embodiments of the present invention, in the structure shown in formula (III), X 25 It is W or Y, preferably W.

[0338] In some optional embodiments of the present invention, in the structure shown in formula (III), X 28 A, D or E, preferably E.

[0339] In some optional embodiments of the present invention, in the structure shown in formula (III), X 35 A or Q, preferably A.

[0340] In some optional embodiments of the present invention, X 1 Y or H; X 3 Q or H; X 6 is F or F(2-F); X 12 K or I; X 13 Y or L; X 15 D or E; X 16 K or E; X 17 R, K or Q; X 18 A, R or Y; X 19A or Q; X 20 Q, K or Aib; X 23 V or I; X 24 Q or E; X 25 W or Y; X 28 A, D or E; X 29 G or H; X 30 G or H; X 35 It is A or Q.

[0341] In some optional embodiments of the present invention, X 1 Y or H, X 3 H; X 6 is F or F(2-F), X 12 I; X 13 is Y; X 15 E; X 16 K; X 17 R; X 18 is Y; X 19 A; X 20 Aib;X 23 V or I; X 24 Q; X 25 W; X 28 E; X 29 G or H; X 30 G or H; X 35 is A.

[0342] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivative has a structure represented by formula (IV):

[0343] X 1 X 2 X 3 GT-F(2-F)-TSDYX 11 IX 13 LDKCAX 19 CAFIEYLLX 28 GGPSSGAPPPS

[0344] (IV).

[0345] In some optional embodiments of the present invention, in the structure shown in formula (IV), X 1 It is Y or H, preferably Y.

[0346] In some optional embodiments of the present invention, in the structure shown in formula (IV), X 2 For Aib.

[0347] In some optional embodiments of the present invention, in the structure shown in formula (IV), X 3It is Q or H, preferably Q.

[0348] In some optional embodiments of the present invention, in the structure shown in formula (IV), X 13 It is L or αMeL, preferably αMeL.

[0349] In some optional embodiments of the present invention, in the structure shown in formula (IV), X 19 It is Q or H, preferably Q.

[0350] In some optional embodiments of the present invention, in the structure shown in formula (IV), X 28 A or E, preferably A.

[0351] In some optional embodiments of the present invention, X 1 Y or H, X 2 Aib, s, Ac4c or V, X 3 Q or H, X 11 is S or αMeS, X 13 is L or αMeL, X 19 Q or H, X 28 Either A or E.

[0352] In some optional embodiments of the present invention, X 1 is Y; X 2 Aib;X 3 Q; X 11 is S or αMeS; X 13 is αMeL;X 19 Q; X 28 is A.

[0353] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivative has a structure represented by formula (V):

[0354] X 1 -Aib-X 3 GTX 6 TSDY 12 X 13 LX 15 KCX 18 X 19 X 20 X 21 FX 23 CX 25 LLX 28 GGPSSGAPPPS

[0355] (V).

[0356] In some optional embodiments of the present invention, in the structure shown in formula (V), X 1It is Y or H.

[0357] In some optional embodiments of the present invention, in the structure shown in formula (V), X 3 It is Q or H.

[0358] In some optional embodiments of the present invention, in the structure shown in formula (V), X 6 It is F or F(2-F), preferably F.

[0359] In some optional embodiments of the present invention, in the structure shown in formula (V), X 12 It is K or I.

[0360] In some optional embodiments of the present invention, in the structure shown in formula (V), X 13 It is Y, L or A, preferably Y or L.

[0361] In some optional embodiments of the present invention, in the structure shown in formula (V), X 15 It is D or E, preferably D.

[0362] In some optional embodiments of the present invention, in the structure shown in formula (V), X 18 A or Y.

[0363] In some optional embodiments of the present invention, in the structure shown in formula (V), X 19 It is A or Q.

[0364] In some optional embodiments of the present invention, in the structure shown in formula (V), X 20 It is Q, Aib, H or R, preferably Q or Aib.

[0365] In some optional embodiments of the present invention, in the structure shown in formula (V), X 21 It is D, A or L, preferably D or A.

[0366] In some optional embodiments of the present invention, in the structure shown in formula (V), X 25 W or Y.

[0367] In some optional embodiments of the present invention, in the structure shown in formula (V), X 28 A or E, preferably E.

[0368] In some optional embodiments of the present invention, X 1 Y or H, X 3 Q or H, X 6 is F or F(2-F), X 12 K or I, X 13 is Y, L or A, X 15 For D or E, X18 A or Y, X 19 A or Q, X 20 is Q, Aib, H or R, X 21 D, A or L, X 25 W or Y, X 28 Either A or E.

[0369] In some optional embodiments of the present invention, X 1 Y or H; X 3 Q or H; X 6 F;X 12 K or I; X 13 Y or L; X 15 D;X 18 A or Y; X 19 A or Q; X 20 Q or Aib; X 21 D or A; X 25 W or Y; X 28 For E.

[0370] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivative has a structure represented by formula (VI):

[0371] Y-Aib-QGTFTSDYSILLDKZ 1 AQH-Aib-FIEYLLZ 1 GGPSSGAPPPS

[0372] (VI).

[0373] In some optional embodiments of the present invention, two Z 1 Each is independently selected from C or HoC.

[0374] In some optional embodiments of the present invention, two Z 1 Both are C.

[0375] In some optional embodiments of the present invention, two Z 1 All are HoC.

[0376] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivative has a structure represented by formula (VII):

[0377] X 1 X 2 X 3 GTX 6 TX 8 DX 10 X 11 X 12 X 13 X14 X 15 X 16 X 17 X 18 X 19 X 20 Z 1 X 22 X 23 X 24 X 25 LX 27 Z 1 GGPX 32 SX 34 X 3

[0378] 5 PPPS

[0379] (VII).

[0380] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 1 It is Y or H.

[0381] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 2 It is Aib, s or Ac4c.

[0382] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 10 It is Y, L or 4-Pal, preferably Y or 4-Pal.

[0383] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 11 For S.

[0384] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 12 It is K or I.

[0385] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 13 It is Y, L, αMeL, Q, Aib or Iva, and is preferably Y, L, αMeL, Q or Iva.

[0386] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 14 is L, K(Ac), HoL, Npg or Tle.

[0387] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 15 It is D or E.

[0388] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 16 is K(Ac), K, αMeK or E.

[0389] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 17 is R, K, K(Ac), Q or I.

[0390] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 18 is A, R or Y, preferably Y or A.

[0391] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 19 It is A, Q or Aib.

[0392] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 20 It is Q, K, Aib, H, a or C, preferably Aib, a, H or Q.

[0393] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 22 It is F or HoF, preferably F.

[0394] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 24 It is Q or E.

[0395] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 25 W or Y.

[0396] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 32 It is S or P, preferably S.

[0397] In some optional embodiments of the present invention, in the structure shown in formula (VII), X 35 A or K, preferably A.

[0398] In some optional embodiments of the present invention, in the structure shown in formula (VII), two Z 1 Each is independently selected from C, C, HoC or αMeC.

[0399] In some optional embodiments of the present invention, in the structure shown in formula (VII), two Z 1 Both are C.

[0400] In some optional embodiments of the present invention, in the structure shown in formula (VII), two Z1 Both are c.

[0401] In some optional embodiments of the present invention, in the structure shown in formula (VII), two Z 1 All are HoC.

[0402] In some optional embodiments of the present invention, in the structure shown in formula (VII), two Z 1 All are αMeC.

[0403] In some optional embodiments of the present invention, X 1 Y or H; X 2 is Aib, s or Ac4c; X 3 is Q, H or Dab(Ac); X 6 is F, F(2-F) or αMeF; X 8 is S, HoS or αMeS; X 10 Y, L or 4-Pal; X 11 S; X 12 K or I; X 13 is Y, L, αMeL, Q, Aib or Iva; X 14 is L, K(Ac), HoL, Npg or Tle; X 15 D or E; X 16 is K(Ac), K, αMeK or E; X 17 is R, K, K(Ac), Q or I; X 18 A, R or Y; X 19 A, Q or Aib; X 20 is Q, K, Aib, H, a or C; X 21 is C, C, HoC or αMeC; X 22 F or HoF; X 23 V or I;

[0404] X 24 Q or E; X 25 W or Y; X 27 L, K or I; X 28 is C, C, HoC or αMeC; X 32 S or P; X 34 G or Aib; X 35 It is A or K.

[0405] In some optional embodiments of the present invention, X 1 Y or H; X 2 is Aib, s or Ac4c; X 3 is Q, H or Dab(Ac); X 6 is F, F(2-F) or αMeF; X8 is S, HoS or αMeS; X 10 Y or 4-Pal; X 11 S; X 12 K or I; X 13 is Y, L, αMeL, Q or Iva; X 14 is L, K(Ac), HoL, Npg or Tle; X 15 D or E; X 16 is K(Ac), K, αMeK or E; X 17 is R, K, K(Ac), Q or I; X 18 is Y or A; X 19 A, Q or Aib; X 20 is Q, K, Aib, H, a or C; X 21 is C, C, HoC or αMeC; X 22 F;X 23 V or I; X 24 Q or E; X 25 W or Y; X 27 L, K or I; X 28 is C, C, HoC or αMeC; X 34 G or Aib; X 32 S; X 35 is A.

[0406] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivative has a structure represented by formula (VIII):

[0407] YX 2 QGTX 6 TSDYSIX 13 LDX 16 X 17 AQX 20 X 21 FIEYLLX 28 GGPSSGAPPPS

[0408] (VIII).

[0409] In some optional embodiments of the present invention, in the structure shown in formula (VIII), X 2 It is Aib or Ac4c.

[0410] In some optional embodiments of the present invention, in the structure shown in formula (VIII), X 6 is F(2-F) or F.

[0411] In some optional embodiments of the present invention, in the structure shown in formula (VIII), X 13It is αMeL, Q or L.

[0412] In some optional embodiments of the present invention, in the structure shown in formula (VIII), X 16 is αMeK or K.

[0413] In some optional embodiments of the present invention, in the structure shown in formula (VIII), X 17 is K(Ac) or K.

[0414] In some optional embodiments of the present invention, in the structure shown in formula (VIII), X 20 Is Aib or K.

[0415] In some optional embodiments of the present invention, in the structure shown in formula (VIII), X 21 It is K or A.

[0416] In some optional embodiments of the present invention, in the structure shown in formula (VIII), X 28 It is K or A.

[0417] In some optional embodiments of the present invention, the two side chains in the structure shown in formula (VIII) contain -NH 2 The amino acid Z 2 The positions are 17 and 20, or 21 and 28 respectively.

[0418] In some optional embodiments of the present invention, the two side chains in the structure shown in formula (VIII) contain -NH 2 The amino acid Z 2 The positions are 17 and 20 respectively.

[0419] In some optional embodiments of the present invention, the two side chains in the structure shown in formula (VIII) contain -NH 2 The amino acid Z 2 The positions are 21 and 28 respectively.

[0420] In some optional embodiments of the present invention, in the structure shown in formula (VIII), the two amino acids Z 2 Each is independently selected from K, k, αMeK, HoK, Dap, Dab, Orn or N-Me-K, preferably K or Orn.

[0421] In some optional embodiments of the present invention, in the structure shown in formula (VIII), the two amino acids Z 2 Both are K.

[0422] In some optional embodiments of the present invention, in the structure shown in formula (VIII), the two amino acids Z 2 Both are Orn.

[0423] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivative has a structure represented by formula (IX):

[0424] Y-Aib-QGTX 6 TSDYSI-αMeL-LDX 16 -K(Ac)-AQ-Aib-Z 2 FIEYLLZ 2 GGPSSGAPPPS

[0425] (IX).

[0426] In some optional embodiments of the present invention, in the structure shown in formula (IX), X 6 is F(2-F).

[0427] In some optional embodiments of the present invention, in the structure shown in formula (IX), X 16 is αMeK or K.

[0428] In some optional embodiments of the present invention, in the structure shown in formula (IX), two Z 2 Each independently selected from K or Orn;

[0429] In some optional embodiments of the present invention, in the structure shown in formula (IX), two Z 2 All are K;

[0430] In some optional embodiments of the present invention, in the structure shown in formula (IX), two Z 2 Both are Orn.

[0431] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivative has a structure represented by formula (X):

[0432] YX 2 QGTX 6 TSDYSIX 13 LDKKAQKAFIEYLLAGGPSSGAPPPS

[0433] (X).

[0434] In some optional embodiments of the present invention, in the structure shown in formula (X), X 2 It is Aib or Ac4c.

[0435] In some optional embodiments of the present invention, in the structure shown in formula (X), X 6 is F(2-F) or F.

[0436] In some optional embodiments of the present invention, in the structure shown in formula (X), X 13 It is αMeL, Q or L.

[0437] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivative has at least one of the following structures:

[0438] Y-Aib-QGTFTSDYSKYCDKRAAQCFVQWLLAGGPSSGAPPPS;

[0439] Y-Aib-QGTFTSDYSKYCDEKRAKCFVQWLLDHPSSGQPPPS;

[0440] Y-Aib-QGTFTSDCSKYCDERAAQDFVQWLLAGGPSSGAPPPS;

[0441] Y-Aib-QGTFTSDCSKYLDECAAQDFVQWLLAGGPSSGAPPPS;

[0442] Y-Aib-QGTFTSDCSKYLDERAAQCFVQWLLAGGPSSGAPPPS;

[0443] H-Aib-HGTFTSDYSIYCEKKYAQCFVQWLLAGGPSSGAPPPS;

[0444] H-Aib-HGTFTSDYSIYCEKRYAQCFVQWLLAGGPSSGAPPPS;

[0445] H-Aib-HGTFTSDYSIYCEKRYA-Aib-CFVQWLLEGGPSSGAPPPS;

[0446] Y-Aib-QGTFTSDYSKYLDKCAAQDFVCWLLAGPGPSSGAPPPS;

[0447] H-Aib-HGTFTSDYSKYLDKCYAQDFVCWLLEGGPSSGAPPPS;

[0448] Y-Aib-QGTFTSDYSILLDKCAQHAFICYLLEGPGPSSGAPPPS;

[0449] Y-Aib-QGTFTSDYSILLDKCAQ-Aib-AFICYLLEGPSSGAPPPS;

[0450] <h2 style=";text-align:left;direction:ltr">H-Aib-HGTFTSDYSRALEKCAARLFICWLLEGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0451] <h2 style=";text-align:left;direction:ltr"> H-Aib-HGTFTSDYSKYLE-K(Ac)-KYA-Aib-CFVQWLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0452] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0453] <h2 style=";text-align:left;direction:ltr"> H-Aib-HGTFTSDLSKL-K(Ac)-EEQRQ-Aib-CFIEWLKCGGPPS-Aib-KPPPK;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0454] <h2 style=";text-align:left;direction:ltr"> H-Aib-QGTFTSDLSKQ-K(Ac)-DEQRAKCFIEWLICGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0455] <h2 style=";text-align:left;direction:ltr"> H-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0456] <h2 style=";text-align:left;direction:ltr"> (3-iodo-Y)-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0457] <h2 style=";text-align:left;direction:ltr"> (4-Pal)-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0458] <h2 style=";text-align:left;direction:ltr"> (4-amino-F)-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;Ys-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0459] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-αMeF-TSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0460] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFT-HoS-DYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0461] <h2 style=";text-align:left;direction:ltr">Y-Aib-QGTFTSDYSI-αMeL-HoL-DK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0462] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-Npg-DK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0463] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-Tle-DK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0464] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEWLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0465] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSILLDK-K(Ac)-AQ-Aib-CFIEWLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0466] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LDKQAQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0467] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-a-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0468] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQHCFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0469] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQQCFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0470] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-A-Aib-QCFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0471] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LDKRAQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0472] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LEK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0473] <h2 style=";text-align:left;direction:ltr">Y-Aib-QGTFTSDYSI-αMeL-L-Aad-KK(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0474] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSD-4-Pal-SI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0475] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFT-αMeS-DYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0476] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0477] <h2 style=";text-align:left;direction:ltr"> Y-Aib-Dab(Ac)-GTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0478] <h2 style=";text-align:left;direction:ltr"> Y-Aib-HGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0479] <h2 style=";text-align:left;direction:ltr"> Y-Ac4c-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0480] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSILLDKCAQH-Aib-FIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0481] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSILLDK-HoC-AQH-Aib-FIEYLL-HoC-GGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0482] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSILLDKCAQQAFICYLLAGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0483] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSILLDKQAQQCFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0484] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSI-Aib-LDK-K(Ac)-AQQCFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0485] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSILCDKQAQQCFIEYLLAGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0486] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSILLD-αMeK-K(Ac)-AQQCFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0487] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSILLD-αMeK-K(Ac)-AQ-Aib-CFIEYLICGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0488] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSI-Iva-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0489] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDY-αMeS-ILLD-αMeK-K(Ac)-AQQCFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0490] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LD-αMeK-K(Ac)-AQQCFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0491] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LD-αMeK-K(Ac)-AQQC-HoF-IEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0492] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LDKCAQCAFIEYLLAGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0493] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSI-Iva-LDKCAQCAFIEYLLAGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0494] <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDY-αMeS-I-αMeL-LD-αMeK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0495] Y-Aib-QGT-F(2-F)-TSDY-αMeS-I-αMeL-LD-αMeK-CAQCAFIEYLLAGGPSSGAPPPS\H-Aib-HGT-F(2-F)-TSDYSIYLE-K(Ac)-KYA-Aib-CFVQWLLCG\GPSSGAPPPS

[0496] H-Aib-HGT-F(2-F)-TSDYSIQ-K(Ac)-EEIAQ-Aib-CFIEWLLCGGPSSGAPPPS;

[0497] H-Aib-HGT-F(2-F)-TSDYSIY-K(Ac)-EERAQ-Aib-CFIEWLLCGGPSSGAPPPS;

[0498] H-Aib-HGT-F(2-F)-TSDYSI-Iva-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS\

[0499] Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LDKCAHCAFIEYLLAGGPSSGAPPPS;

[0500] Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LDKCA-K(Ac)-CAFIEYLLAGGPSSGAPPPS;

[0501] Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LDKCAQCAFIEYLLAGGPSSGAPPPS;

[0502] H-Aib-HGT-F(2-F)-TSDYSI-αMeL-LDKCAQCAFIEYLLAGGPSSGAPPPS;

[0503] Ys-QGT-F(2-F)-TSDYSI-αMeL-LDKCAQCAFIEYLLAGGPSSGAPPPS;

[0504] Y-Aib-QGTFTSDSDYSILLDKQAQQCFIEYLLCGGPSSGAPPPS;

[0505] Y-Ac4c-QGT-F(2-F)-TSDYSILLDKCAQCAFIEYLLEGGPSSGAPPPS;

[0506] Y-Ac4c-QGT-F(2-F)-TSDYSILLDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;

[0507] H-Ac4c-HGT-F(2-F)-TSDYSIQLEEIAQ-Aib-CFIEYLLCGGPSSGAPPPS?

[0508] Y-Aib-QGTFTSDSDYSILLDK-K(Ac)-AQ-Aib-c-FIEYLL-c-GGPSSGAPPPS\

[0509] Y-Aib-QGTFTSDSDYSILLDK-K(Ac)-AQ-Aib-Hoc-FIEYLL-Hoc-GGPSSGAPPPS;

[0510] Y-Aib-QGTFTSDYSILLDK-K(Ac)-AQ-Aib-αMeC-FIEYLL-αMeC-GGPSSGAPPPS;

[0511] Y-Aib-QGT-F(2-F)-TSDYSIQLDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS;

[0512] Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LD-αMeK-K(Ac)-AQ-Aib-KFIEYLLKGGPSSGAPPPS;

[0513] Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-KFIEYLLKGGPSSGAPPPS;

[0514] Y-Aib-QGTFTSDYSILLDK-K(Ac)-AQ-Aib-Orn-FIEYLL-Orn-GGPSSGAPPPS;

[0515] Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LDKKKAQKAFIEYLLAGGPSSGAPPPS;

[0516] Y-Aib-QGT-F(2-F)-TSDYSIQLDKKAQKAFIEYLLAGGPSSGAPPPS;

[0517] Y-Aib-QGTFTSDSDYSILLDKKKKKAFIEYLLAGGPSSGAPPPS!

[0518] Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LDKKAQKAFIEYLLAGGPSSGAPPPS.

[0519] It should be noted that the “-” between the amino acids in the above polypeptide represents an amide bond; illustratively, the “-” in “Y-Aib-Q” represents an amide bond.

[0520] In this document, "(3-iodo-Y)" means 3-iodo-Y, "(4-Pal)" means 4-Pal, and the above-mentioned "(4-amino-F)" means 4-amino-F. However, "-" in F(2-F), (3-iodo-Y), (4-Pal) and (4-amino-F) does not represent an amide bond.

[0521] According to an embodiment of the present invention, a modifying group is further included.

[0522] According to an embodiment of the present invention, the modifying group is in contact with one or two amino acids Z containing -SH in the side chain of the polypeptide or its derivatives represented by formula (I). 1 , or one or both of the side chains contain -NH 2 The amino acid Z 2 connected.

[0523] According to an embodiment of the present invention, the modifying group and the two amino acids Z containing -SH in the side chains of the polypeptide or its derivatives represented by formula (I) are 1 connected simultaneously; or

[0524] The modifying group and the two side chains in the polypeptide or its derivatives represented by formula (I) contain -NH 2 The amino acid Z 2 Connected at the same time.

[0525] According to an embodiment of the present invention, the modifying group is connected to the -SH group of the amino acid C side chain via a sulfur-carbon bond.

[0526] According to an embodiment of the present invention, the modifying group is connected to the ε-amino group of the side chain of amino acid K via an amide bond.

[0527] According to an embodiment of the present invention, the modifying group has a structure shown in formula (XI):

[0528]

[0529] Among them, R 1 C, N, -C 3~10 Heteroalkylene, -C 3~10 Arylene or -C3~10 heteroarylene;

[0530] R 2 and R 3 Each independently is optionally replaced by one or more R 1a Replaced-C 1~6 Alkylene-, optionally one or more R 1a Substituted-NH-C(O)-C 1~6 Alkylene- or optionally one or more R 1a Replaced-C 1~6 Alkylene-NH-C(O)-C 1~6 Alkylene-, wherein each R 1a are independently halogen, -OH, -SH, -NH 2 、-NO 2 , -CN, phenyl, -C 1~6 Alkyl, -C 1~6 Haloalkyl or -C 1~6 Alkoxy;

[0531] R 4 Empty, or optionally replaced by one or more R 2a Replaced-C 1~6 Alkylene-NH-C(O)-C 1~6 Alkylene-, wherein each R 2a are independently halogen, -OH, -SH, -NH 2 、-NO 2 , -CN, phenyl, -C 1~6 Alkyl, -C 1~6 Haloalkyl or -C 1~6 Alkoxy;

[0532] R 5 H, -C 1~6 Alkoxy or -C 1~6 Alkyl, wherein the -C 1~6 Alkyl and -C 1~6 The alkoxy groups are each independently optionally substituted with one or more halogen, -OH, -C(O)OH, -C(O)-, -SH, -NH 2 、-NO 2 , -CN substitution;

[0533] R 6 is optionally replaced by one or more R 3a Replaced-C 1~6 Alkylene-, or optionally one or more R 3a Replaced-(C 1~3 Alkylene-O) m1 -C 1~6 Alkylene-, wherein each R3a are independently halogen, -OH, -SH, -NH 2 、-NO 2 , -CN, phenyl, -C 1~6 Alkyl, -C 1~6 Haloalkyl or -C 1~6 Alkoxy;

[0534] R 7 is optionally replaced by one or more R 4a Replaced-C 1~6 Alkylene-, wherein each R 4a are independently halogen, -OH, -SH, -NH 2 、-NO 2 , -CN, phenyl, -C 1~6 Alkyl, -C 1~6 Haloalkyl or -C 1~6 Alkoxy;

[0535] R 8 is optionally replaced by one or more R 5a Replaced-C 10~20 Alkyl, optionally with one or more R 5a Replaced-C 10~20 Alkylene-R 9 , optionally one or more R 5a Replaced-C 5~10 Alkylene-OC 3~10 Arylene-R 9 , or optionally one or more R 5a Replaced-C 5~10 Alkylene-OC 3~10 Heteroarylene-R 9 , where each R 5a are independently halogen, -OH, -SH, -NH 2 、-NO 2 , -CN, phenyl, -C 1~6 Alkyl, -C 1~6 Haloalkyl or -C 1~6 Alkoxy;

[0536] R 9 -COOH, -C 3~7 Heteroaryl, -S(O) 2 OH, or -PO(OH) 2 ;

[0537] m1 is any integer from 1 to 6;

[0538] n1 is any integer from 0 to 6;

[0539] n2 is any integer from 1 to 10.

[0540] It should be noted that the “-” in the modifying group in the present invention represents a chemical bond connecting chemical groups, such as a covalent bond between atoms (or atoms in a group) and atoms (or atoms in a group).

[0541] According to an embodiment of the present invention, R 1 C, N, -C 5~7 Heteroalkylene, -C 5~7 Arylene or -C 5~7 Heteroarylene.

[0542] According to an embodiment of the present invention, R 1 It is N, N-, N-phenylene or N-pyridylene.

[0543] According to an embodiment of the present invention, R 1 for

[0544] According to an embodiment of the present invention, R 2 and R 3 Each independently is -C 1~6 Alkylene-, or -C 1~6 Alkylene-NH-C(O)-C 1~6 Alkylene-.

[0545] According to an embodiment of the present invention, R 2 and R 3 Each independently is -C 1~3 Alkylene-, or -C 1~3 Alkylene-NH-C(O)-C 1~3 Alkylene-.

[0546] According to an embodiment of the present invention, each n1 is independently 0, 1, 2, 3, 4 or 5.

[0547] According to an embodiment of the present invention, n1 is 0.

[0548] According to an embodiment of the present invention, R 4 Empty or -C 1~6 Alkylene-NH-C(O)-C 1~6 Alkylene-.

[0549] According to an embodiment of the present invention, R 4 Empty or -C 1~3 Alkylene-NH-C(O)-C 1~3 Alkylene-.

[0550] According to an embodiment of the present invention, R 5 H, -C 1~3 Alkoxy or -C 1~3 alkyl.

[0551] According to an embodiment of the present invention, R 6 For -C 1~6 Alkylene-, -(C 1~3 Alkylene-O) m1 -C 1~6 Alkylene-.

[0552] According to an embodiment of the present invention, R 6 For -C 1~3 Alkylene-, -(C 1~3 Alkylene-O) m1 -C 1~3 Alkylene-.

[0553] According to an embodiment of the present invention, m1 is 2, 3, 4 or 5.

[0554] According to an embodiment of the present invention, R 7 For -C 1~6 Alkylene-.

[0555] According to an embodiment of the present invention, R 7 For -C 2~4 Alkylene-.

[0556] According to an embodiment of the present invention, R 8 For -C 10~20 Alkyl, -C 10~20 Alkylene-R 9 , -C 5~10 Alkylene-OC 3~10 Arylene-R 9 , or -C 5~10 Alkylene-OC 3~10 Heteroarylene-R 9 .

[0557] According to an embodiment of the present invention, R 8 For -C 10~18 Alkyl, -C 14~18 Alkylene-R 9 , or -C 7~9 Alkylene-OC 5~7 Arylene-COOH.

[0558] According to an embodiment of the present invention, R 9 -COOH, -C 5~6 Heteroaryl, -S(O) 2 OH, or -PO(OH) 2 .

[0559] According to an embodiment of the present invention, R 9 -COOH, -S(O) 2OH, -PO(OH) 2 ,or

[0560] According to an embodiment of the present invention, n2 is 1, 2 or 3.

[0561] According to an embodiment of the present invention, n2 is 3, 4, 5 or 6.

[0562] According to an embodiment of the present invention, the modifying group represented by formula (XI) has a structure represented by formula (XIa):

[0563]

[0564] Among them, each R 10 and R 11 Each independently is -C 0~3 Alkylene-;

[0565] R 12 For -C 1~6 Alkylene-;

[0566] R 8 For -C 10~21 Alkyl, or -C 10~21 Alkylene-COOH, preferably -C 14~19 Alkyl or -C 10~18 Alkylene-COOH;

[0567] q1 is 1, 2, 3, or 4;

[0568] q2 is 1, 2, or 3.

[0569] According to an embodiment of the present invention, the modifying group represented by formula (XIa) has one of the following structures:

[0570]

[0571]

[0572]

[0573]

[0574] According to an embodiment of the present invention, the modifying group represented by formula (XI) has a structure represented by formula (XIb):

[0575]

[0576] Among them, each R 10 ' and R 11 'Each independently -C 0~3 Alkylene-;'

[0577] R 12 'For -C 1~6 Alkylene-;

[0578] R 13 For -C 10~20 Alkylene-, preferably -C 14~18 Alkylene-;

[0579] q1' is 1, 2, 3 or 4;

[0580] q2' is 1, 2 or 3.

[0581] According to an embodiment of the present invention, the modifying group represented by formula (XIb) has one of the following structures:

[0582]

[0583] According to an embodiment of the present invention, the modifying group represented by formula (XI) has a structure represented by formula (XIc):

[0584]

[0585] Among them, each R 14 Each independently is -C 1~3 Alkylene-or-NH-C(O)-C 1~3 Alkylene-;

[0586] R 15 For -C 0~3 Alkylene-or-C(O)-NH-C 1~3 Alkylene-;

[0587] R 12 " for -C 1~6 Alkylene-;

[0588] R 13 'For -C 10~20 Alkylene-, preferably -C 14~18 Alkylene-;

[0589] q1” is 1, 2, 3 or 4;

[0590] q2” is 1, 2 or 3;

[0591] Y 1 It is C or N.

[0592] According to an embodiment of the present invention, the modifying group represented by formula (XIc) has one of the following structures:

[0593]

[0594]

[0595] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivatives contains two amino acids Z containing -SH on their side chains. 1 , the modifying group has a structure represented by formula (XI).

[0596] According to an embodiment of the present invention, the modifying group has a structure shown in formula (XII):

[0597]

[0598] Among them, R 20 C, N, -C 3~10 Arylene or -C 3~10 heteroarylene;

[0599] R 21 and R 22 Each is independently empty, optionally replaced by one or more R 1b Replaced-C 1~6 Alkylene-, or optionally one or more R 1b Replaced-C 1~6 Oxyalkylene-, wherein each R 1b are independently halogen, -OH, -SH, -NH 2 、-NO 2 , -CN, phenyl, -C 1~6 Alkyl, -C 1~6 Haloalkyl or -C 1~6 Alkoxy;

[0600] R 23 Empty, optionally replaced by one or more R 2b Replaced-C 1~6 Alkylene-, optionally with one or more R 2b Substituted -C(O)-C 1~6 Alkylene-, optionally with one or more R 2b Substituted-NH-C(O)-C 1~6 Alkylene-, or optionally one or more R 2b Replaced-C 1~6 Alkylene-C(O)-NH-C 1~6 Alkylene-, wherein each R 2b are independently halogen, -OH, -SH, -NH 2 、-NO 2 , -CN, phenyl, -C 1~6 Alkyl, -C 1~6 Haloalkyl or -C 1~6 Alkoxy;

[0601] R 24 is optionally replaced by one or more R 3b Replaced-C 1~6 Alkylene-, or optionally one or more R 3b Replaced-(C 1~3 Alkylene-O) m2 -C 1~6 Alkylene-, wherein each R 3b are independently halogen, -OH, -SH, -NH 2 、-NO 2 , -CN, phenyl, -C 1~6 Alkyl, -C 1~6 Haloalkyl or -C 1~6 Alkoxy;

[0602] R 25 H, -C 1~6 Alkoxy or -C 1~6 Alkyl, wherein the -C 1~6 Alkyl and -C 1~6 The alkoxy groups are each independently optionally substituted with one or more halogen, -OH, -C(O)OH, -C(O)-, -SH, -NH 2 、-NO 2 , -CN substitution;

[0603] R 26 is optionally replaced by one or more R 4b Replaced-C 1~6 Alkylene-, wherein each R 4b are independently halogen, -OH, -SH, -NH 2 、-NO 2 , -CN, phenyl, -C 1~6 Alkyl, -C 1~6 Haloalkyl or -C 1~6 Alkoxy;

[0604] R 27 is optionally replaced by one or more R 5b Replaced-C 10~20 Alkyl, optionally with one or more R 5b Replaced-C 10~20 Alkylene-R 28 , optionally one or more R 5b Replaced-C 5~10 Alkylene-OC 3~10 Arylene-R 28 , or optionally one or more R 5b Replaced-C 5~10 Alkylene-OC 3~10Heteroarylene-R 28 , where each R 5b are independently halogen, -OH, -SH, -NH 2 、-NO 2 , -CN, phenyl, -C 1~6 Alkyl, -C 1~6 Haloalkyl or -C 1~6 Alkoxy;

[0605] R 28 -COOH, -C 3~7 Heteroaryl, -S(O) 2 OH, or -PO(OH) 2 ;

[0606] m2 is any integer from 1 to 6;

[0607] n3 is any integer from 1 to 10;

[0608] n3 is 0, 1 or 2;

[0609] Y 2 Empty or NH.

[0610] According to an embodiment of the present invention, R 20 C, N, -C 5~7 Arylene or -C 5~7 Heteroarylene.

[0611] According to an embodiment of the present invention, R 20 It is C, N, phenylene or pyridylene.

[0612] According to an embodiment of the present invention, R 20 for Preferably

[0613] According to an embodiment of the present invention, R 21 and R 22 Each is independently empty, -C 1~6 Alkylene-, or -C 1~6 Oxyalkylene-.

[0614] According to an embodiment of the present invention, R 21 and R 22 Each is independently empty or -C 1~3 Alkylene-.

[0615] According to an embodiment of the present invention, R 23 Empty, -C 1~6 Alkylene-, -C 1~6 Alkylene-C(O)-NH-C 1~6 Alkylene-, or -C(O)-C1~6 Alkylene-.

[0616] According to an embodiment of the present invention, R 23 Empty, -C 1~3 Alkylene-, or -C(O)-C 2~4 Alkylene-.

[0617] According to an embodiment of the present invention, R 24 For -C 1~6 Alkylene-, or -(C 1~3 Alkylene-O) m2 -C 1~6 Alkylene-.

[0618] According to an embodiment of the present invention, R 24 For -C 1~3 Alkylene-, or -(C 1~3 Alkylene-O) m2 -C 1~3 Alkylene-.

[0619] According to an embodiment of the present invention, m2 is 2, 3, 4 or 5.

[0620] According to an embodiment of the present invention, R 25 H, -C 1~6 Alkoxy or -C 1~6 alkyl.

[0621] According to an embodiment of the present invention, R 25 H or -C 1~3 alkyl.

[0622] According to an embodiment of the present invention, R 26 For -C 1~6 Alkylene-.

[0623] According to an embodiment of the present invention, R 26 For -C 1~3 Alkylene-.

[0624] According to an embodiment of the present invention, R 27 For -C 10~20 Alkyl, -C 10~20 Alkylene-R 28 , -C 5~10 Alkylene-OC 3~10 Arylene-R 28 , or -C 5~10 Alkylene-OC 3~10 Heteroarylene-R 28 .

[0625] According to an embodiment of the present invention, R 27 For -C 10~18Alkyl, -C 14~18 Alkylene-R 28 , or -C 7~9 Alkylene-OC 5~7 Arylene-COOH.

[0626] According to an embodiment of the present invention, R 28 -COOH, -C 5~6 Heteroaryl, -S(O) 2 OH, or -PO(OH) 2 .

[0627] According to an embodiment of the present invention, R 28 -COOH, -S(O) 2 OH, -PO(OH) 2 ,or

[0628] According to an embodiment of the present invention, p is 1, 2 or 3.

[0629] According to an embodiment of the present invention, p is 3, 4, 5 or 6.

[0630] According to an embodiment of the present invention, the modifying group represented by formula (XII) has a structure represented by formula (XIIa):

[0631]

[0632] Among them, each R 29 Each independently is -C 1~3 Alkylene-;

[0633] R 30 -C(O)-C 1~6 Alkylene-, or -C 1~3 Alkylene-C(O)-NH-C 1~3 Alkylene-;

[0634] R 31 For -C 1~6 Alkylene-;

[0635] q3 is 1, 2, 3 or 4;

[0636] q4 is 1, 2 or 3.

[0637] According to an embodiment of the present invention, the modifying group represented by formula (XIIa) has one of the structures shown below:

[0638]

[0639]

[0640]

[0641] According to an embodiment of the present invention, the modifying group represented by formula (XII) has a structure represented by formula (XIIb):

[0642]

[0643] Among them, each R 29 'Each independently -C 1~3 Alkylene-;

[0644] R 30 'For -C 1~6 Alkylene-;

[0645] R 31 'For -C 1~6 Alkylene-;

[0646] q3' is 1, 2, 3 or 4, preferably 2;

[0647] q4' is 1, 2 or 3, preferably 2.

[0648] According to an embodiment of the present invention, R 27 For -C 10~20 Alkylene -COOH or -C 10~20 Alkyl, preferably -C 14~18 Alkylene-COOH.

[0649] According to an embodiment of the present invention, the modifying group represented by formula (XIIb) has one of the structures shown below:

[0650]

[0651]

[0652] According to an embodiment of the present invention, the modifying group represented by formula (XII) has a structure represented by formula (XIIc):

[0653]

[0654] Among them, R 30 "-C 1~6 Alkylene-;

[0655] R 31 "-C 1~6 Alkylene-;

[0656] q3 is 1, 2, 3 or 4;

[0657] q4 is 1, 2 or 3.

[0658] According to an embodiment of the present invention, R27 For -C 10~20 Alkylene -COOH or -C 10~20 Alkyl, preferably -C 14~18 Alkylene -COOH or -C 10~19 alkyl.

[0659] According to an embodiment of the present invention, the modifying group represented by formula (XIIc) has one of the structures shown below:

[0660]

[0661] According to an embodiment of the present invention, the polypeptide represented by formula (I) or its derivatives contain two side chains containing -NH 2 The amino acid Z 2 , the modifying group has a structure represented by formula (XIIc).

[0662] In some optional embodiments of the present invention, the polypeptide represented by formula (I) or its derivative has at least one of the structures shown in Table A below:

[0663] Table A

[0664]

[0665]

[0666]

[0667]

[0668] It should be noted that the "attachment site of the modification group" in Table A is specifically X i The position of i in .

[0669] Pharmaceutical compositions, uses and methods

[0670] In the second aspect of the present invention, the present invention proposes a pharmaceutical composition. According to an embodiment of the present invention, the pharmaceutical composition comprises the polypeptide or its derivatives or their pharmaceutically acceptable salts described in the first aspect. As mentioned above, the polypeptide or its derivatives or their pharmaceutically acceptable salts of the present invention exhibit strong agonist activity on the three receptor targets of GLP-1R, GCGR and GIPR, and can effectively control blood sugar and reduce body weight. Therefore, the use of drugs containing polypeptides or their derivatives or their pharmaceutically acceptable salts can effectively prevent or treat metabolic disorder-related diseases, bone-related diseases, cardiovascular diseases and neurodegenerative diseases, etc.

[0671] According to an embodiment of the present invention, it further includes a pharmaceutically acceptable excipient.

[0672] In the third aspect of the present invention, the present invention proposes a use of the polypeptide or its derivatives or their pharmaceutically acceptable salts described in the first aspect or the pharmaceutical composition described in the second aspect in the preparation of a drug, wherein the drug is used to treat or prevent at least one of metabolic disorder-related diseases, bone-related diseases, cardiovascular diseases and neurodegenerative diseases.

[0673] According to an embodiment of the present invention, the metabolic disorder-related diseases include at least one of obesity, diabetes, dyslipidemia-related diseases, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.

[0674] According to an embodiment of the present invention, the neurodegenerative disease includes at least one of Alzheimer's disease and Parkinson's disease.

[0675] In the fourth aspect of the present invention, the present invention provides a method for preventing and / or treating metabolic disorder-related diseases, bone-related diseases, cardiovascular diseases and / or neurodegenerative diseases. According to an embodiment of the present invention. The method comprises: administering to a subject a pharmaceutically acceptable amount of the polypeptide or its derivatives or their pharmaceutically acceptable salts described in the first aspect or the pharmaceutical composition described in the second aspect. The method of the present invention can effectively prevent and / or treat metabolic disorder-related diseases, bone-related diseases, cardiovascular diseases and / or neurodegenerative diseases.

[0676] According to an embodiment of the present invention, the metabolic disorder-related diseases include at least one of obesity, diabetes, dyslipidemia-related diseases, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.

[0677] According to an embodiment of the present invention, the neurodegenerative disease includes at least one of Alzheimer's disease and Parkinson's disease.

[0678] The effective amount of the polypeptide or its derivative, or the pharmaceutical composition of the present invention may vary with the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated, the patient's weight, the patient's immune status, the route of administration, etc. For example, several divided doses may be administered daily, or the dose may be reduced proportionally, depending on the urgency of the treatment situation.

[0679] The polypeptide or its derivatives, or the pharmaceutical composition of the present invention can be incorporated into a drug suitable for parenteral administration (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). These drugs can be prepared in various forms. For example, liquid, semisolid and solid dosage forms, etc., including but not limited to liquid solutions (e.g., injection solutions and infusion solutions) or lyophilized powders. Typical drugs are in the form of injection solutions or infusion solutions. The aforementioned polypeptide or its derivatives, or the pharmaceutical composition can be administered by intravenous infusion or injection or intramuscular or subcutaneous injection.

[0680] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.

[0681] Example 1: Preparation method of polypeptide or its derivatives

[0682] 1. The linear peptides in peptides 1 to 83 (abbreviated as TG01 to TG83) in Table A were synthesized using the classic Fmoc-tBu solid phase synthesis method. X peptide synthesizer was prepared, and the reaction conditions were as follows:

[0683] (1) Resin swelling: Add Rink Amide MBHAresin resin into DCM at room temperature. 2 The mixture was reacted by blowing air for 1 hour, filtered, and the resin was washed with DMF 2-3 times.

[0684] (2) Removal of Fmoc protecting group: Add DMF solution containing 20% ​​piperidine to the above resin and heat at room temperature. 2 The reaction was carried out by blowing air for 10 minutes, and the mixture was filtered and the above operation was repeated until the deprotection was complete. The resin was washed with DMF for 2-3 times.

[0685] (3) Amino acid coupling: The materials were added in a reaction ratio of resin: amino acid: DIC: Oxyma Pure = 1:5:5:5. The reactants, DIC and Oxyma Pure were pre-dissolved in DMF and heated at room temperature for 2 h. 2 The reaction was carried out by blowing air for 10 minutes, and then the mixture was transferred to a resin reaction tank and heated at room temperature under N 2 The reaction was carried out by blowing air for 1-3 hours, and after the reaction was completed, the resin was filtered and washed with DMF for 2-3 times. After the synthesis was completed, the resin was washed with DCM for 2-3 times and vacuum dried to obtain the peptide resin.

[0686] The above method is applicable to the following amino acids (D or L form) or synthetic reagents including but not limited to: Fmoc-AEEA-OH, Fmoc-Aad(tBu)-OH, Fmoc-Ac4c-OH, Fmoc-Aib-OH, Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Dab(Ac)-OH, Fmoc-Dap(Ac)-OH, Fmoc-Gly-OH, Fmoc-Gl u(tBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Iva-OH, Fmoc-Leu-OH, Fmoc-Lys(Ac)-OH, Fmo c-Lys(Boc)-OH, Fmoc-Lys(Mtt)-OH, Fmoc-Lys(Alloc)-OH, Fmoc-Lys(ivDde)-OH, Fmoc-Met-OH, Fmoc-Nal-OH, Fmoc-Nl e-OH, Fmoc-Orn(Boc)-OH, Fmoc-Pal-OH, Fmoc-Pro-OH, Fmoc-Phe-OH, Fmoc-Phe(2-F)-OH, Fmoc-Phe(3-F)-OH, Fmoc-Ph e(4-F)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Tle-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Val-O H, Fmoc-α-methyl-Leu-OH, Fmoc-α-methyl-Lys(Boc)-OH, Fmoc-α-methyl-Phe-OH, Fmoc-α-methyl-Phe(2-F)-OH, Fmoc -AEEA-OH, Fmoc-Glu-OtBu, Fmoc-Asp-OtBu, Fmoc-Ida(Allyl)-OH, Boc-L-His(Trt)-OH, Boc-L-Tyr(tBu)-OH, Myristic acid, Myristic acid, Stearic acid, Arachidic acid, Docosanoic acid, 18-(tert-butoxy)-18-oxooctadecanoic acid, 20-(tert-Butoxy)-20-oxoicosanoic acid, etc.

[0687] 2. Linear peptide cutting and drying: According to TFA:TIPS:H 2The peptide cutting solution was prepared in a volume ratio of O:EDT = 95:2:2:1. The cutting solution (10 mL / g resin) was added to the dried peptide resin, and the mixture was placed on a shaker for 3 hours. The resin residue was filtered, and 10 times the volume of cold MTBE was added to the filtrate. The resulting suspension was cooled at -20°C for 1 hour, and then centrifuged at 3500 rpm. The precipitate was washed 3-5 times with cold MTBE, and the crude peptide was obtained by vacuum drying.

[0688] 3. Purification of linear peptides: Prepare a dissolving solution according to the volume ratio of mobile phase A (0.1% TFA-water): mobile phase B (0.1% TFA-acetonitrile) = 1.5:1, dissolve the crude peptide in the dissolving solution to prepare a storage solution, filter with a 0.45-micron filter membrane, use a C18 reverse phase preparative column (20*250mm, particle size 5μm) at a flow rate of 10mL / min using mobile phase A and mobile phase B for gradient elution, collect the target peak, and lyophilize to obtain the target peptide compound (i.e., linear peptide).

[0689] 4. The preparation of the Staple linker (or modified group A) was carried out by the classic Fmoc-tBu solid phase synthesis method. This step takes Staple-A1 (or modified group A1) as an example, and the reaction conditions are as follows (for the specific process, see Figure 1 ):

[0690] (1) Resin swelling: Fmoc-L-Lys(ivDde)-2CTC resin was added to DCM at room temperature. 2 The mixture was reacted by blowing air for 1 hour, filtered, and the resin was washed with DMF 2-3 times.

[0691] (2) Removal of Fmoc protecting group: Add DMF solution containing 20% ​​piperidine to the above resin and heat at room temperature. 2 The reaction was carried out by blowing air for 10 minutes, and the mixture was filtered and the above operation was repeated until the deprotection was complete. The resin was washed with DMF for 2-3 times.

[0692] (3) Fatty acid chain coupling: The materials were added in a reaction ratio of resin: fatty acid: HATU: DIPEA = 1:5:5:10. Fatty acid mono-tert-butyl ester, HATU and DIPEA were pre-dissolved in DMF and heated at room temperature for 2 h. 2 The reaction was carried out by blowing air for 10 minutes, and then the mixture was transferred to a resin reaction tank and heated at room temperature under N 2 The reaction was carried out by blowing air for 1-3 hours. After the reaction was completed, the resin was filtered and washed with DMF 2-3 times.

[0693] (4) Removal of ivDde protecting group: Add DMF solution containing 5% hydrazine to the resin and heat at room temperature. 2 The reaction was allowed to react by blowing air for 10 minutes, and this operation was repeated 2-3 times until it was completely removed, and the resin was washed with DMF 2-3 times.

[0694] (5) Coupling of amino acid, AEEA and bromoacetic acid: The materials were added in a reaction ratio of resin: Fmoc-AA-OH: DIC: Oxyma Pure = 1:5:5:5. The reactants, DIC and Oxyma Pure were pre-dissolved in DMF and heated at room temperature for 2 h. 2 The reaction was carried out by blowing air for 10 minutes, and then the mixture was transferred to a resin reaction tank and heated at room temperature under N 2 The reaction was carried out by blowing air for 1-3 hours, and after the reaction was completed, the resin was filtered and washed with DMF for 2-3 times. After the synthesis was completed, the resin was washed with DCM for 2-3 times and vacuum dried to obtain the linker resin.

[0695] Staple linkers can also be selected from the following structures:

[0696]

[0697]

[0698] 5. Coupling of linear peptides with Staple linkers:

[0699] 1.0 equivalent of linear peptide (i.e., the target peptide compound obtained in step 3, this step takes peptide 30 (abbreviated as TG30) in Table A as an example) and 1.2 equivalent of Staple linker (i.e., the Staple linker obtained in step 4) were dissolved in a reaction solution with a volume ratio of PBS:acetonitrile = 1:1.5 (final concentration of 1.2 mM), the pH of the reaction solution was adjusted to 8.0 with a 10% NaOH aqueous solution, and the reaction solution was fully shaken at room temperature on a shaker for 3-8 hours until the linear peptide was completely consumed by LC-MS detection, and the reaction solution was neutralized to pH 6.5 with a 5% TFA aqueous solution, filtered with a 0.45 μm filter membrane, and gradient eluted with mobile phase A and mobile phase B at a flow rate of 10 mL / min using a C18 reverse phase preparative column (20*250 mm, particle size 5 μm), the target peak was collected, and lyophilized to obtain the target coupling compound (i.e., the peptide derivative). For the specific process, see Figure 2 The purity and mass spectrometry of each polypeptide derivative were identified. The purity was greater than 90% after HPLC detection. The molecular weight of the polypeptide identified by mass spectrometry was basically consistent with the theoretical molecular weight (all within the error tolerance range). The molecular weights of some polypeptide molecules are shown in this example. See Table 1 for details.

[0700] Table 1: Molecular weight of compounds

[0701]

[0702]

[0703] Example 2: Preparation method of polypeptide or its derivatives

[0704] 1. The linear peptides in peptides 84 to 94 (abbreviated as TG84 to TG94) in Table A were synthesized using the classic Fmoc-tBu solid phase synthesis method. X peptide synthesizer was prepared, and the reaction conditions were as follows:

[0705] (1) Resin swelling: Add Rink Amide MBHA resin to DCM at room temperature. 2 The mixture was reacted by blowing air for 1 hour, filtered, and the resin was washed with DMF 2-3 times.

[0706] (2) Removal of Fmoc protecting group: Add DMF solution containing 20% ​​piperidine to the above resin and heat at room temperature. 2 The reaction was carried out by blowing air for 10 minutes, and the mixture was filtered and the above operation was repeated until the deprotection was complete. The resin was washed with DMF for 2-3 times.

[0707] (3) Amino acid coupling: The materials were added in a reaction ratio of resin: Fmoc-AA-OH: DIC: Oxyma Pure = 1:5:5:5. Fmoc-AA-OH, DIC and Oxyma Pure were pre-dissolved in DMF and heated at room temperature for 2 h. 2 The reaction was carried out by blowing air for 10 minutes, and then the mixture was transferred to a resin reaction tank and heated at room temperature under N 2 The reaction was carried out by aeration for 1-3 hours. After the reaction was completed, the resin was filtered and washed with DMF 2-3 times. The amino acids at the N-terminal end of the sequence were Boc-L-His(Trt)-OH, Boc-L-Tyr(tBu)-OH and other amino acids, which were also synthesized using the above method. After the synthesis was completed, the resin was washed with DCM 2-3 times and vacuum dried to obtain a peptide resin containing a linear peptide.

[0708] The above method is applicable to, including but not limited to, the following amino acids (D or L form) or synthetic reagents: Fmoc-AEEA-OH, Fmoc-Aad(tBu)-OH, Fmoc-Ac4c-OH, Fmoc-Aib-OH, Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Dab(Ac)-OH, Fmoc-Dap(Ac)-OH, Fmoc-Gly-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Iva-OH, Fmoc-Leu-OH, Fmoc-Lys(Ac)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Mtt)-OH, Fmoc-Lys(Alloc)-OH, Fmoc-Lys(ivDde)-OH, Fmoc-Met-OH, Fmoc-Nal-OH, Fmoc-Nle-OH, Fmoc-Orn(Boc)-OH, Fmoc-Pal-OH, Fmoc-Pro-OH, Fmoc-Phe-OH, Fmoc-Phe(2-F)-OH, Fmoc-Phe(3-F)-OH, Fmoc-Phe(4-F)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Tle-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Val-OH, Fmoc-α-methyl-Leu-OH, Fmoc-α-methyl-Lys(Boc)-OH, Fmoc-α-methyl-Phe-OH, Fmoc-α-methyl-Phe(2-F)-OH, Fmoc-AEEA-OH, Fmoc-Glu-OtBu, Fmoc-Asp-OtBu, Fmoc-Ida(Allyl)-OH, Boc-L-His(Trt)-OH, Boc-L-Tyr(tBu)-OH, Myristic acid, Stearic acid, Arachidic acid, Docosanoic acid, 18-(tert-butoxy)-18-oxooctadecanoic acid, 20-(tert-Butoxy)-20-oxoicosanoic acid, etc.

[0709] 2. The Staple linker (or modification group B) is connected to the peptide resin containing the linear peptide (TG85) obtained in step 1. The specific steps are as follows (for specific processes, see Figure 3 ):

[0710] 2.1 Removal of Mtt protecting group from peptide resin: prepare deprotection solution according to the volume ratio of TFA:TIPS:DCM=1:2:97, add Mtt removing solution (10mL / g resin) to the resin, place on a shaker to fully shake and react for 15 minutes, filter the resin, repeat the process 3-5 times until the color no longer appears bright yellow after the removal solution is added, indicating complete removal, and wash the resin with DMF 2-3 times.

[0711] 2.2 Removal of Alloc and Allyl protecting groups from peptide resin: DCM (10 mL / g resin), PhSiH3 (10 equivalents) and Pd(PPh3)4 (0.1 equivalents) were added to the resin. 2 The reaction was carried out by blowing air for 1 hour, and the resin was filtered by suction. This process was repeated 1-2 times, and the resin was washed with DMF 2-3 times.

[0712] 2.3 Cyclic reaction on peptide resin: DMF (10 mL / g resin), PyBOP (5 equivalents), HOBt (5 equivalents) and DIPEA (10 equivalents) were added to the resin from which the Alloc and Allyl protecting groups were removed. 2 The reaction was carried out by blowing air for 4 hours, and the resin was filtered by suction, and the process was repeated 1-2 times. The resin was washed with DMF 2-3 times.

[0713] 2.4 Solid-phase side chain introduction: According to the standard solid-phase synthesis method, the side chain has the following structure:

[0714]

[0715] 3. Cutting and drying: According to TFA: TIPS: H 2 The peptide cutting solution was prepared in a volume ratio of O:EDT = 95:2:2:1. The cutting solution (10 mL / g resin) was added to the dried resin, and the resin was placed on a shaker for 3 hours. The resin residue was filtered, and 10 times the volume of cold MTBE was added to the filtrate. The resulting suspension was cooled at -20 ° C for 1 hour, and then centrifuged at 3500 rpm. The precipitate was washed 3-5 times with cold MTBE, and the crude peptide was obtained by vacuum drying.

[0716] 4. Peptide purification: Prepare a dissolving solution according to the volume ratio of mobile phase A (0.1% TFA-water): mobile phase B (0.1% TFA-acetonitrile) = 1.5:1, dissolve the crude peptide in the dissolving solution to prepare a storage solution, filter with a 0.45 micron filter membrane, use a C18 reverse phase preparation column (20*250 mm, particle size 5μm) at a flow rate of 10 mL / min to use mobile phase A and mobile phase B for gradient elution, collect the target peak, and freeze-dry to obtain the target peptide derivatives, namely polypeptide 84 to polypeptide 94 (abbreviated as TG84 to TG94). The purity and mass spectrometry of each polypeptide derivative were identified, among which, after HPLC detection, the purity was greater than 90%; the molecular weight of the polypeptide identified by mass spectrometry was basically consistent with the theoretical molecular weight (all within the error allowable range). The molecular weight of some polypeptide molecules is exemplified in this embodiment, see Table 2 for details.

[0717] Table 2: Molecular weight of compounds

[0718]

[0719] Test Example 1: In vitro activity assay

[0720] 1. Insulin analogs can bind to target receptors on the cell membrane, activate cAMP response elements (CRE), and start the expression of downstream luciferase. The expression level is positively correlated with the biological activity of the tested analog. After activation, luciferase substrate is added for chemiluminescence detection, and its luminescence intensity is measured to characterize the biological activity of the test compound. Therefore, the CreLuc method can be used to detect the target peptide derivatives (or polypeptide derivatives, i.e., TG1 to TG94) prepared in Example 1 and Example 2. The specific steps are as follows:

[0721] HEK293 / pGM-CREB-L-Luc / GLP-1R pool, HEK293 / pGM-CREB-L-Luc / GIPRpool, and 293HEK / pGM-CREB-L-Luc / GCGR pool stable transfection cell lines were constructed. The target peptide derivatives (TG1-TG94) prepared in Example 1 and Example 2 were diluted 5-fold from the highest 100 nM to prepare a dilution series containing 11 concentration gradients. GIP and Glucagon were used as positive controls for the test. A dilution series was prepared in the same way for the test. The corresponding test cells were digested (1 min) and centrifuged (1000 rpm, 5 min). After the culture medium was discarded, the cells were suspended with freestyle culture medium, centrifuged, collected and counted, and diluted to a cell density of 5×10 5100 μL / mL and add to the detection wells of a 384-well plate (40 μL / 20,000 / well). Use Echo to add the corresponding test dilution series. After incubating the cell plate at 37°C and 5% carbon dioxide for 6 hours, add ONE-GLO (20 μL / well) for detection, place it away from light for 3 minutes, measure it with a chemiluminescent microplate reader, read the plate within 30 minutes, and record the measurement results. Use GraphPad Prism software to draw the activation curve and calculate the EC of the target peptide derivative. 50 The results are shown in Table 3. The results show that the polypeptide derivatives of the present invention have binding activity with GLP-1R, GIPR and GCGR.

[0722] Table 3: EC of each target peptide derivative 50 value

[0723]

[0724]

[0725] 2. Insulin analogs can bind to target receptors on the cell membrane, activate the receptors and release them. The activity of the test substance can be determined by using a cAMP detection kit and the HTRF method. Therefore, the target peptide derivatives (or polypeptide derivatives, i.e., TG1 to TG86) prepared in Example 1 and Example 2 can be detected by the cAMP method. The specific steps are as follows:

[0726] HEK293 / pGM-CREB-L-Luc / GLP-1 pool, HEK293 / pGM-CREB-L-Luc / GIP pool, and HEK293 / pGM-CREB-L-Luc / GCG pool stable transfection cell lines were constructed. The target peptide derivatives (TG1-TG86) prepared in Example 1 and Example 2 were diluted 5-fold from the highest 100 nM to prepare a dilution series containing 11 concentration gradients. GIP and Glucagon were used as positive controls for the test, and a dilution series was prepared in the same way for the test. The test cell line was selected and digested with cAMP-specific trypsin, and then 3 mL of serum-free DMEM medium was added and suspended by pipetting, and the cells were counted. 5 μL of IBMX (prepared with serum-free DMEM medium, 0.5 mM) and test cells (5 μL / 7500 / well) were added to the 384-well plate in sequence. After culturing at 37°C and 5% carbon dioxide for 30 minutes, cAMP-d2 (5 μL, 1x) and Anti-cAMP-Cryptate (5 μL, 1x) were added, and the plates were placed at room temperature for 1 hour. The HTRF value was measured using a chemiluminescence microplate reader, and the measurement results were recorded. The activation curve was drawn using GraphPad Prism software, and the EC value of the target peptide derivative was calculated. 50 The results are shown in Table 4. The results show that the polypeptide derivatives of the present invention have binding activity with GLP-1R, GIPR and GCGR.

[0727] Table 4: EC of each target peptide derivative 50 value

[0728]

[0729] The polypeptide derivative disclosed in patent PCT / CN2022 / 097622 was prepared by the method described in Example 1 and Example 2, and the polypeptide derivative was prepared by the CreLuc method. The results showed that the polypeptide derivative only had binding activity to two receptors among GLP-1R, GIPR, and GCCR, and it could not have agonist activity to the three receptors of GLP-1R, GIPR, and GCCR at the same time. Test Example 2: In vivo pharmacokinetic evaluation

[0730] The target peptide derivatives (or polypeptide derivatives, i.e.

[0731] The pharmacokinetic behavior of (TG1-TG94) in rodents was tested. The specific steps are as follows:

[0732] The target peptide derivatives (TG1-TG94) to be tested were administered to male SD rats by subcutaneous injection (SC, 3 mg / kg, drug solvent was PBS, concentration was 1.5 mg / mL, and the administration volume was 2 mL) and intravenous injection (IV, 1 mg / kg, drug solvent was PBS, concentration was 0.5 mg / mL, and the administration volume was 2 mL). After administration, whole blood samples were collected from the jugular vein or other appropriate veins at the following time points: SC, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h; IV, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h. 0.2 mL of blood was collected and placed in a labeled EDTA-K2 anticoagulant tube. After gently inverting the tube upside down to fully mix the anticoagulant (EDTA-K2) with the blood, immediately place it in wet ice and centrifuge it as quickly as possible to separate the plasma. The centrifugation conditions are set at 4°C, 6800×g, and 6 minutes. The plasma sample is stored in a refrigerator not higher than -20°C until it is used for analysis.

[0733] Under ice-water bath yellow light conditions, in addition to the blank sample, add 300 μL of precipitant containing internal standard to the 96-well plate containing 20 μL of standard curve sample, quality control sample or unknown sample; add 300 μL of acetonitrile to the blank sample. Vortex mix, then centrifuge. Take 150 μL of supernatant after centrifugation to a new 96-well plate, and then add 150 μL of ultrapure water to mix. The above samples were quantitatively analyzed by LC-MS analysis, and gradient elution was performed using XB-C18 (2.1*100mm, 3μm) chromatography, and the mobile phase used was: mobile phase A = 0.1% formic acid-water; mobile phase B = acetonitrile. Phoenix WinNonlin software was used to calculate the pharmacokinetic parameters, and the results showed that the polypeptide derivatives of the present invention were well absorbed in rats, with high blood drug concentration and long half-life. The pharmacokinetic parameter detection results of some polypeptide derivatives are shown in Table 5A and Table 5B.

[0734] Table 5A: Pharmacokinetic parameters of each target peptide derivative

[0735]

[0736] Table 5B: Pharmacokinetic parameters of each target peptide derivative

[0737]

[0738] Test Example 3: In vivo pharmacodynamics study

[0739] Take 23-26 week old DIO male C57BL / 6J mice, with a body weight of 45-55g and a blood glucose range of 8-12mmol / L. The DIO mice were randomly divided into groups, and 6 mice in each group were adaptively raised in a cage for 1 week. During this period, they were kept on a high-fat diet and had free access to drinking water. After the pre-adaptation of the animals, the basal blood glucose and body weight of each mouse were tested before administration (Day 0). Then, according to the experimental groups, the vehicle control (Vehicle), Tirzepatide (10nmol / kg) and three doses of the compound TG52 of the present invention (3nmol / kg, 10nmol / kg, 30nmol / kg) were given subcutaneous injection (sc). After the administration, normal high-fat diet and drinking water were given. The blood glucose level, body weight and total daily food intake of each group of mice were tested on Day 1, 2, 3, 4, 5, 6 and 7 after administration, and the changes in blood glucose, body weight (% of the initial value) and total daily food intake of each group of mice were calculated. The curve was drawn. The results are shown in Figures 4 to 6 .

[0740] Test Example 4: Study on the stability against enzymatic degradation

[0741] The stability of the target peptide derivatives (or polypeptide derivatives, i.e. (TG1-TG94) prepared in Example 1 and Example 2 in artificial gastric juice (SGF) and artificial small intestinal fluid (SIF) was tested. The specific steps are as follows:

[0742] The target peptide derivatives (TG1-TG94) to be tested were dissolved in PBS to prepare a stock solution (60 μM), and 15 μL was diluted with 285 μL of commercial artificial gastric juice (SGF) and incubated in a 37°C water bath. Equal amounts of solution (30 μL) were extracted at 0 min, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h and 8 h, and 0.2 M Na 2 CO 3 The aqueous solution (30 μL) was used for neutralization reaction, and the remaining peptide amount was analyzed by LC-MS method. The relative percentage of the peptide amount corresponding to the 0 min time at different times was calculated. The degradation curve was drawn using GraphPad Prism to calculate the half-life (T) of the target peptide derivative in SGF. 1 / 2 ).

[0743] The test compound was dissolved in PBS to prepare a storage solution (60uM), and 15μL was taken and diluted with 285μL of commercial artificial gastric juice (SGF) and incubated in a 37°C water bath. Equal amounts of solution (30μL) were extracted at 0min, 5min, 15min, 30min, 1h, 2h, 4h and 8h, respectively, and the reaction was neutralized with 10% TFA-water solution (30μL). The remaining peptide amount was analyzed by LC-MS, and the relative percentage of the peptide amount corresponding to the 0min time at different times was calculated. The degradation curve was drawn using GraphPad Prism, and the half-life (T) of each target peptide derivative in SIF was calculated. 1 / 2 ). The results showed that all target peptide derivatives had good stability against enzymatic degradation.

[0744] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0745] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A polypeptide or its derivative or a pharmaceutically acceptable salt thereof, characterized in that: The polypeptide or its derivative has a structure and a modifying group as shown in formula (I): X1X2X3GTX6TSDX 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 FX 23 X 24 X 25 LLX 28 GGPSSGAPPPS (I); Wherein, X1 is Y or H; X2 is Aib, s, or Ac4c; X3 is Q, H or Dab(Ac); X6 is F, F(2-F) or αMeF; X 10 Y, or 4-Pal; X 11 is S or αMeS; X 12 is K or I; X 13 is Y, L, αMeL, Q, or Iva; X 14 is Z1, L, K(Ac), HoL, Npg or Tle; X 15 D or E; X 16 is K, E, K(Ac), or αMeK; X 17 is R, Z2, Z1, K(Ac), Q or I; X 18 is A or Y; X 19 A, or Q; X 20 is Q, Z2, Aib, H, a or Z1; X 21 is Z1, D, A, or Z2; X 23 V or I; X 24 is Q, Z1 or E; X 25 is W or Y; X 28 is A, E, Z1 or Z2; Condition a) or b): a) In the structure represented by formula (I), two sites in any of the following groups are independently selected from amino acids Z1 having a side chain containing -SH: 1) 14 and 21, or 2) 17 and 24, or 3) 17 and 20, or 4) 21 and 28; The two amino acids Z1 having -SH in the side chains are independently selected from C, C, αMeC, HoC, Hoc, Pen or N-Me-C, the modifying group has a structure shown in formula (XI), and the modifying group is simultaneously connected to the two amino acids Z1; The structure represented by the formula (XI) is selected from the structure represented by the formula (XIa), the formula (XIb) or the formula (XIc): (XIa); Among them, each R 10 and R 11 Each independently is -C 0~3 Alkylene-; R 12 For -C 1~6 Alkylene-; R8 is -C 10~20 Alkyl, -C 10~20 Alkylene-R9, -C 5~10 Alkylene-OC 3~10 Arylene-R9, or -C 5~10 Alkylene-OC 3~10 Heteroarylene-R9; q1 is 1, 2, 3, or 4; q2 is 1, 2, or 3; (XIb); Among them, each R 10 ' and R 11 'Each independently -C 0~3 Alkylene-; R 12 'For -C 1~6 Alkylene-; R 13 For -C 10~20 Alkylene-; q1' is 1, 2, 3 or 4; q2' is 1, 2 or 3; (XIc); Among them, each R 14 Each independently is -C 1~3 Alkylene-or-NH-C(O)-C 1~3 Alkylene-; R 15 For -C 0~3 Alkylene-or-C(O)-NH-C 1~3 Alkylene-; R 12 '' is -C 1~6 Alkylene-; R 13 'For -C 10~20 Alkylene-; q1'' is 1, 2, 3 or 4; q2'' is 1, 2 or 3; Y1 is C or N; b) In the structure represented by formula (I), two sites in any of the following groups are independently selected from amino acid Z2 having a side chain containing -NH2: 1) 17 and 20, or 2) 21 and 28; The two amino acids Z2 containing -NH2 on the side chains are independently selected from K, k, αMeK, HoK, Dap, Dab, Orn or N-Me-K, the modifying group has a structure shown in formula (XII), and the modifying group is simultaneously connected to the two amino acids Z2; The structure represented by formula (XII) is selected from the structure represented by formula (XIIa), formula (XIIb) or formula (XIIc): (XIIa); Among them, each R 29 Each independently is -C 1~3 Alkylene-; R 30 -C(O)-C 1~6 Alkylene-, or -C 1~3 Alkylene-C(O)-NH-C 1~3 Alkylene-; R 31 For -C 1~6 Alkylene-; q3 is 1, 2, 3 or 4; q4 is 1, 2 or 3; (XIIb); Among them, each R 29 'Each independently -C 1~3 Alkylene-; R 30 'For -C 1~6 Alkylene-; R 31 'For -C 1~6 Alkylene-; q3' is 1, 2, 3 or 4; q4' is 1, 2 or 3; (XIIc); Among them, R 30 '' is -C 1~6 Alkylene-; R 31 '' is -C 1~6 Alkylene-; q3 is 1, 2, 3 or 4; q4 is 1, 2 or 3.

2. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X2 is Aib or Ac4c.

3. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X3 is Q or H.

4. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X6 is F or F(2-F).

5. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X6 is F(2-F).

6. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 13 is L or αMeL.

7. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 13 It is Y, L or A.

8. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 13 It is αMeL, Y or Iva.

9. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 13 It is αMeL, Q or L.

10. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 13 It is Y or L.

11. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 14 is L, K(Ac), HoL, Npg or Tle.

12. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 14 is C, L, K(Ac), HoL, Npg or Tle.

13. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 16 K or E.

14. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 16 is K or αMeK.

15. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 17 is C, Q, K(Ac), R or I.

16. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 17 is R, K, K(Ac), Q or I.

17. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 17 is K(Ac) or K.

18. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 17 is C or K(Ac).

19. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 17 It is R, K or Q.

20. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 20 It is Q, K, Aib, H, a or C.

21. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 20 It is Aib, Q, H, C or a.

22. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 20 It is Q, K or Aib.

23. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 20 Is Aib or Q.

24. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 20 Is Aib or K.

25. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 21 It is D, A or C.

26. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 21 It is K or A.

27. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 21 It is D or C.

28. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 24 It is Q, C or E.

29. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 24 Is E or C.

30. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 24 It is Q or E.

31. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 28 A, E, C or HoC.

32. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 28 Either A or E.

33. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 28 Is E or C.

34. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: X 28 It is K or A.

35. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The polypeptide represented by formula (I) or its derivative has a structure represented by formula (Ib): X1X2X3GTX6TSDYX 11 X 12 X 13 LDX 16 X 17 X 18 X 19 X 20 X 21 FX 23 X 24 X 25 LLX 28 GGPSSGAPPPS (Ib).

36. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 35, characterized in that: In the structure represented by formula (Ib), the positions of the two amino acids Z1 having -SH in their side chains are 17 and 24, or 21 and 28, respectively.

37. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The polypeptide represented by formula (I) or its derivative has a structure represented by formula (III): X1-Aib-X3GTX6TSDYSX 12 X 13 Z1X 15 X 16 X 17 X 18 X 19 X 20 Z1FX 23 X 24 X 25 LLX 28 GGPSSGAPPPS (III).

38. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The polypeptide represented by formula (I) or its derivative has a structure represented by formula (IV): X1X2X3GT-F(2-F)-TSDYX 11 IX 13 LDKZ1AX 19 Z1AFIEYLLX 28 GGPSSGAPPPS (IV).

39. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The polypeptide represented by formula (II) or its derivative has a structure represented by formula (V): X1-Aib-X3GTX6TSDYSX 12 X 13 LX 15 KCX 18 X 19 X 20 X 21 FX 23 CX 25 LLX 28 GGPSSGAPPPS (V)。 40. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The polypeptide represented by formula (I) or its derivative has a structure represented by formula (VI): Y-Aib-QGTFTSDYSILLDKZ1AQH-Aib-FIEYLLZ1GGPSSGAPPPS (VI).

41. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 40, characterized in that: The two Z1 are each independently selected from C or HoC.

42. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 40, characterized in that: Both Z1 are C.

43. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 40, characterized in that: Both Z1s are HoC.

44. The polypeptide or its derivative or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The polypeptide represented by formula (I) or its derivative has a structure represented by formula (VII): X1X2X3GTX6TX8DX 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 Z1X 22 X 23 X 24 X 25 LX 27 Z1GGPX 32 SX 34 X 35 PPPS (VII).

45. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 44, characterized in that: Two Z1 are each independently selected from C, C, HoC or αMeC.

46. ​​The polypeptide or derivative thereof or pharmaceutically acceptable salt thereof according to claim 44, characterized in that: Both Z1 are C.

47. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 44, characterized in that: Both Z1 are c.

48. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 44, characterized in that: Both Z1s are HoC.

49. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 44, characterized in that: Both Z1 are αMeC.

50. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The polypeptide represented by formula (I) or its derivative has a structure represented by formula (VIII): YX2QGTX6TSDYSIX 13 LDX 16 X 17 AQX 20 X 21 FIEYLLX 28 GGGSSGAPPPS (VIII).

51. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The polypeptide represented by formula (I) or its derivative has a structure represented by formula (IX): <h2 style=";text-align:left;direction:ltr">Y-Aib-QGTX6TSDYSI-αMeL-LDX<h2 style=";text-align:left;direction:ltr"> 16 <h2 style=";text-align:left;direction:ltr"> -K(Ac)-AQ-Aib-Z2FIEYLLZ2GGPSSGAPPPS (IX).

52. The polypeptide or derivative thereof or pharmaceutically acceptable salt thereof according to claim 51, characterized in that: The two Z2 are each independently selected from K or Orn.

53. The polypeptide or derivative thereof or pharmaceutically acceptable salt thereof according to claim 51, characterized in that: Both Z2 are K.

54. The polypeptide or derivative thereof or pharmaceutically acceptable salt thereof according to claim 51, characterized in that: Both Z2 are Orn.

55. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The polypeptide represented by formula (I) or its derivative has a structure represented by formula (X): YX2QGTX6TSDYSIX 13 LDKKAQKAFIEYLLAGGPSSGAPPPS (X)。 56. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The polypeptide represented by formula (I) or its derivative has at least one of the following structures: H-Aib-HGTFTSDYSIYCEKRYA-Aib-CFVQWLLEGGPSSGAPPPS; H-Aib-HGTFTSDYSKYLDKCYAQDFVCWLLEGGPSSGAPPPS; Y-Aib-QGTFTSDYSILLDKCAQ-Aib-AFICYLLEGPSSGAPPPS; H-Aib-HGTFTSDYSKYLE-K(Ac)-KYA-Aib-CFVQWLLCGGPSSGAPPPS; Y-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; H-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; Ys-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; Y-Aib-QGT-αMeF-TSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; Y-Aib-QGTFTSDYSI-αMeL-HoL-DK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; Y-Aib-QGTFTSDYSI-αMeL-Npg-DK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; Y-Aib-QGTFTSDYSI-αMeL-Tle-DK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; Y-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEWLLCGGPSSGAPPPS; Y-Aib-QGTFTSDYSILLDK-K(Ac)-AQ-Aib-CFIEWLLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr">Y-Aib-QGTFTSDYSI-αMeL-LDKQAQ-Aib-CFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-a-CFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQHCFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQQCFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LDKRAQ-Aib-CFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSDYSI-αMeL-LEK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGTFTSD-4-Pal-SI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-Dab(Ac)-GTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-HGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Ac4c-QGTFTSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSI-Iva-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDY-αMeS-ILLD-αMeK-K(Ac)-AQQCFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LDKCAQCAFIEYLLAGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDY-αMeS-I-αMeL-LD-αMeK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; <h2 style=";text-align:left;direction:ltr"> Y-Aib-QGT-F(2-F)-TSDY-αMeS-I-αMeL-LD-αMeK-CAQCAFIEYLLAGGPSSGAPPPS; H-Aib-HGT-F(2-F)-TSDYSIQ-K(Ac)-EEIAQ-Aib-CFIEWLLCGGPSSGAPPPS; H-Aib-HGT-F(2-F)-TSDYSI-Iva-LDK-K(Ac)-AQ-Aib-CFIEYLLCGGPSSGAPPPS; Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LDK-K(Ac)-AQ-Aib-KFIEYLLKGGPSSGAPPPS; Y-Aib-QGT-F(2-F)-TSDYSI-αMeL-LDKKAQKAFIEYLLAGPGPSSGAPPPS.

57. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The modifying group is connected to the -SH of the amino acid C side chain via a sulfur-carbon bond; or The modifying group is connected to the ε-amino group of the amino acid K side chain via an amide bond.

58. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R8 is -C 10~18 Alkyl, -C 14~18 Alkylene-R9, or -C 7~9 Alkylene-OC 5~7 Arylene-COOH.

59. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R8 is -C 10~21 Alkyl, or -C 10~21 Alkylene-COOH.

60. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R8 is -C 14~19 Alkyl or -C 10~18 Alkylene-COOH.

61. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The modifying group represented by the formula (XIa) has the structure shown below: ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; 。 62. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R 13 For -C 14~18 Alkylene-.

63. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The modifying group represented by the formula (XIb) has the structure shown below: ; 。 64. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R 13 ' is C 14~18 Alkylene-.

65. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The modifying group represented by the formula (XIc) has the structure shown below: ; ; 。 66. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R 27 For -C 10~20 Alkylene -COOH or -C 10~20 alkyl.

67. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R 27 For -C 14~18 Alkylene -COOH or -C 10~19 alkyl.

68. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The modifying group represented by the formula (XIIa) has the structure shown below: ; ; ; ; ; ; ; ; ; ; ; ; ; ; 。 69. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: q3' is 2; and / or q4' is 2.

70. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R 27 For -C 10~20 Alkylene -COOH or -C 10~20 alkyl.

71. The polypeptide or its derivative or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R 27 For -C 14~18 Alkylene-COOH.

72. The polypeptide or derivative thereof or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The modifying group represented by the formula (XIIb) has the structure shown below: ; ; ; ; ; 。 73. The polypeptide or derivative thereof or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R 27 For -C 10~20 Alkylene -COOH or -C 10~20 alkyl.

74. The polypeptide or its derivative or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R 27 For -C 14~18 Alkylene -COOH or -C 10~19 alkyl.

75. The polypeptide or derivative thereof or pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The modifying group represented by the formula (XIIc) has the structure shown below: ; 。 76. A polypeptide derivative or a pharmaceutically acceptable salt thereof, characterized in that: The polypeptide derivative has any structure shown in Table A: Table A Wherein, the structure of the modification group A1 is: ; The structure of the modifying group B1 is: 。 77. A pharmaceutical composition, characterized in that It includes the polypeptide or its derivative or their pharmaceutically acceptable salts according to any one of claims 1 to 75, or the polypeptide derivative or their pharmaceutically acceptable salts according to claim 76.

78. The pharmaceutical composition according to claim 77, characterized in that It further includes pharmaceutically acceptable excipients or carriers.

79. Use of the polypeptide or its derivative or pharmaceutically acceptable salts according to any one of claims 1 to 75, the polypeptide derivative or pharmaceutically acceptable salts according to claim 76, or the pharmaceutical composition according to any one of claims 77 to 78 in the preparation of a drug for treating or preventing diseases related to metabolic disorders.

80. The use according to claim 79, characterized in that The metabolic disorder-related diseases include dyslipidemia-related diseases.

81. The use according to claim 79, characterized in that The metabolic disorder-related diseases include at least one of obesity, diabetes, fatty liver disease, and metabolic syndrome.

82. The use according to claim 79, characterized in that The metabolic disorder-related diseases include non-alcoholic fatty liver disease.

83. The use according to claim 79, characterized in that The metabolic disorder-related diseases include non-alcoholic steatohepatitis.

Citation Information

Patent Citations

  • Triple agonist of glucagon-like peptide-1 receptor, glucagon receptor and gastric inhibitory peptide receptor

    CN111040022A

  • Pharmaceutical composition comprising insulin and triple agonist having activity with respect to all of glucagon and GLP-1 and GIP receptor

    CN113453703A